Pharmaceutical Company List

Transcription

Abbott Laboratories, Inc.
Abbott Park, Illinois
For more than a century, Abbott Laboratories has been working to advance health care for people around the
world. Founded by a young Chicago physician, Dr. Wallace Calvin Abbott, in 1888, Abbott Laboratories has
evolved into a diversified health care company that discovers, develops, manufactures and markets innovative
products and services that span the continuum of care – from prevention and diagnosis to treatment and cure.
Headquartered in north suburban Chicago, Abbott helps people around the world in the more than 130 countries.
Building leadership and combining strengths in the areas of pharmaceuticals, nutritionals, hospital products and
diagnostics has enabled Abbott to provide total, integrated solutions across the health care spectrum for some of
the world’s most prevalent medical conditions, including AIDS, cancer and diabetes. We focus on advancing
medical science and the practice of health care with expertise in the therapeutic areas of diabetes, pain
management, respiratory infections, HIV/AIDS, men and women’s health, pediatrics and animal health.
Abgenix, Inc.
Fremont, California
We are a biopharmaceutical company that develops and intends to commercialize antibody therapeutic products
for the treatment of a variety of disease conditions, including cancer, inflammatory and autoimmune disorders,
transplant-related diseases, cardiovascular disease and infectious diseases. We have proprietary technologies that
facilitate rapid generation of highly specific, antibody therapeutic product candidates that contain fully human
protein sequences and that bind to disease targets appropriate for anti body therapy. We refer to these candidates
as fully human antibody therapeutic candidates. We developed our XenoMouse® technology, a technology using
genetically modified mice to generate fully human antibodies. We also own a technology that enables the ra pid
identification of antibodies with desired function and characteristics, referred to as SLAM™ technology. In our
XenoMax™ technology, we use SLAM technology to select and isolate antibodies with particular function and
characteristics from antibody-producing cells generated by XenoMouse animals. We believe XenoMax technology
enhances our capabilities in product development and flexibility in manufacturing. We intend to use our
technologies to build a large and diversified product portfolio that we expect to develop and commercialize
through licensing arrangements with pharmaceutical companies and others, through joint development and
through internal product development programs. We have entered into a variety of contractual arrangements with
multiple pharmaceutical, biotechnology and genomics companies involving our XenoMouse technology. Two of our
customers, Pfizer and Amgen, have initiated clinical trials with fully human antibodies generated from XenoMouse
animals. In addition, as of March 31, 2002, we had four proprietary antibody product candidates in clinical trials,
one of which we had agreed to co-develop and commercialize with Immunex Corporation and one of which we had
agreed to co-develop and commercialize with SangStat Medical Corporation.
Abraxis Oncology
We are Abraxis Oncology, tapping into our creativity to outsmart tumor biology, attack cancer cells, and surpass
expectations. Our imaginations have free reign to attempt new ideas, lead us down unexplored pathways, and
respectfully challenge established paradigms. With this creative freedom comes innovation —the essential spark in
the quest for new answers and novel treatments. At Abraxis Oncology, we are devoted entirely to develo ping and
promoting innovative, next-generation cancer therapies. Abraxis Oncology is the proprietary division of Abraxis
BioScience (ABBI). Abraxis BioScience is an integrated global biopharmaceutical company focused on the
discovery, development and delivery of next-generation therapeutic moieties for the treatment of life-threatening
diseases.
aaiPharma, Inc.
Wilmington, North Carolina
aaiPharma Inc. is a science-based, specialty pharmaceutical company with more than 22 years of drug
development experience. Focusing on targeted therapeutic areas, the Company markets a growing portfolio of
established branded products and applies innovative technologies to increase the commercial potential of these
products. At the same time, aaiPharma's research and development organization is developing an impressive
pipeline of products to position the Company for near-term and long-term growth in its targeted therapeutic
areas. In addition to developing and marketing its own line of proprietary pharmaceutical products, aaiPharma
continues to be a world leader in providing contract pharmaceutical development services through its AAI
International division. NOTE: Merger with CIMA Labs announced 8/05/2003, ter minated 11/03/2003.
ActivBiotics, Inc.
128 Spring Street
Lexington, Massachusetts 02421
ActivBiotics is a clinical stage company committed to significantly improving the treatment of acute infec tions and
chronic diseases caused or exacerbated by microbial pathogens. The Company's lead compound, rifalazil, is being
investigated in a Phase II trial for sexually transmitted diseases and is preparing to enter Phase II trials in other
indications. In addition, the Company has a highly productive program to develop proprietary new chemical
entities. The program is producing both narrow and broad spectrum compounds with unprecedented potency and
concomitantly improved resistance profile.
Adolor Corporation
Exton, Pennsylvania
Adolor Corporation is a late-stage biopharmaceutical company committed to the development and
commercialization of novel products to relieve pain and reduce the side effects of c urrently marketed narcotics.
Adolor’s lead product candidate, alvimopan™, is a first-in-class compound that is in Phase 3 clinical trials for two
indications: post-operative ileus and opioid bowel dysfunction, both of which represent large unmet medical
needs. The company is also developing a series of next-generation peripherally acting kappa opioid compounds for
the treatment of pain associated with acute and chronic inflammatory diseases. These compounds have the
potential to revolutionize existing pain management markets because of their ability to relieve pain as effectively
as morphine and other opioid narcotics, without the severe adverse side effects and addiction potential associated
with opioid narcotics. Adolor’s strategy is to combine near-term commercialization opportunities with a longerterm approach to develop novel opioid analgesics based upon a new molecular understanding of the function of
opioid receptors. Adolor combines the expertise of world leaders in molecular biology, pharmacology an d
chemistry with experienced pharmaceutical and biotechnology management. As Adolor moves towards
commercialization, the company continues to add key personnel with clinical development, regulatory and
commercialization expertise. The Company’s strategic g oal is to establish a pharmaceutical franchise in pain
management.
Aerogen, Inc.
Mountain View, California
Aerogen, an emerging specialty pharmaceutical company, is developing inhaler and nebulizer pr oducts, based on
its proprietary aerosol generator technology, for the treatment of respiratory disorders in the home and hospital
markets. Aerogen is also applying its technology to develop products in collaboration with pharmaceutical and
biotechnology companies for the treatment of respiratory and other disorders. Aerogen now markets two Aeroneb
nebulizer systems, one optimized for professional use in the hospital and the other for home use.
Aeterna Laboratories, Inc.
1405 Parc-Technologique Blvd.
Quebec City, Quebec, CANADA G1P 4P5
AEterna Laboratories has an extensive portfolio of marketed and development -stage biopharmaceutical products
focused in oncology and endocrinology. Its lead oncology compound is Neovastat®, a proprietary angiogenesis
inhibitor with multiple mechanisms of action in a Phase III clinical trial for renal cell carcinoma (data available by
year-end 2003) and in a Phase III trial for non-small cell lung cancer. Cetrotide®, its lead compound in
endocrinology is sold in the U.S. and Europe to the "in vitro" fertilization market, and is in clinical testing for
endometriosis, uterus myoma and enlarged prostate (BPH). A further seven clinical programs are underway with
various compounds.
Alcon Laboratories, Inc.
Fort Worth, Texas
From its inception more than 50 years ago, Alcon has committed itself to the discovery and development of
specialty pharmaceuticals that address both chronic and acute diseases of the eye. We are committed not just to
the treatment of a single eye disease or disorder, such as gluacoma, but to all of the major diseases of the eye
including infection, inflammation, allergy, dry e ye and macular degeneration. Over the years, Alcon has become
the global leader in specialty ophthalmic pharmaceuticals, with the broadest array of products of any company in
the industry around the world. With a large sales force covering ophthalmologists , optometrists, pediatricians,
allergists and primary care physicians, we are uniquely positioned in the industry to market effectively to all
physicians and eye care professionals who might prescribe our eye medications.
Alexion Pharmaceuticals
Cheshire, Connecticut
Alexion's strategy is to build on its strong scientific and product development base to develop novel antibody
therapeutics targeting the treatment of patients with a wide array of severe disease states, including
cardiovascular and autoimmune disorders, inflammation and cancer. Alexion is dedicated to developing effective
and safe treatments for human diseases for which treatment options are either non -existent or inadequate.
Alfacell Corporation
225 Belleville Avenue
Bloomfield, New Jersey 07003
Alfacell is a biopharmaceutical company focused on the discovery, development and commercialization of novel
ribonucleases (RNases). Our mission is to develop new therapeutics from our novel ribo nuclease technology
platform for the treatment of cancer, infectious diseases and other life threatening conditions, thus offering new
horizons of hope for patients and physicians.
Allergan, Inc.
Irvine, California
Allergan, Inc., with headquarters in Irvine, California, is a global specialty pharmaceutical company that develops
and commercializes innovative products for the eye care, neuromodulator, skin care and oth er specialty markets.
In addition to its discovery-to-development research programs, Allergan has global marketing and sales
capabilities in over 100 countries that deliver value to our customers, satisfy unmet medical needs and improve
people's lives.
Allos Therapeutics, Inc.
11080 CirclePoint Road Suite 200
Westminster, Colorado 80020
Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative
drugs for improving cancer treatments. The company's lead clinical candidate, RSR13 (efaproxiral), is a synthetic
small molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and enhance the
efficacy of standard radiation therapy. In addition, Allos is developing PDX, a novel small molecule cytotoxic
injectable antifolate (DHFR inhibitor) being developed for non-small cell lung cancer, mesothelioma and nonHodgkin's lymphoma.
Alnylam Pharmaceuticals, Inc.
790 Memorial Drive, Suite 202
Cambridge, Massachusetts 02139
Alnylam is the leading company in the emerging field of RNA interference (RNAi) whose vision is to Harness a
Revolution in Biology for Human Health(TM). Growing from its foundation as the world's first company focused on
RNAi-based therapeutics, the company is built around the leading capabilities of its two operating units, Alnylam
Pharmaceuticals of Cambridge, Massachusetts, and Ribopharma of Kulmbach, Germany. Over the last several
years, RNAi has been identified as a fundamental cellular mechanism for gene silencing. The company's leadership
in the field of RNAi is supported by its preeminent founders and advisors and its strengths in fundamental patents,
technology, and know-how that underlie the commercialization of RNAi -based therapeutics. The company's focus
is to discover, develop, and commercialize therapeutic products based on RNAi for a broad range of therapeutic
indications including viral, oncologic, metabolic, CNS and autoimmune diseases. The company's mission is to lead
research in the field of RNAi, to build the leading pipeline of RNAi -based therapeutics, and to emerge as business
leaders.
Alpha Therapeutic Corporation
Los Angeles, California
Headquartered in Southern California, Alpha Therapeutic has offices and facilities throughout the United States. A
subsidiary, Alpha Therapeutic Services, is a nationwide provider of home infusion produc ts and services. In
addition, the company has international affiliates in the United Kingdom, Germany, Spain, Italy, Thailand and
Singapore.
Alpharma U.S. Pharmaceuticals Division
Baltimore, Maryland
Marketing the broadest portfolio of specialty pharmaceuticals in the industry with over 150 products in both
prescription and over-the-counter categories, Alpharma USPD is a major generic drug compan y with a substantial
presence in consumer pharmaceuticals. Items are available in a wide range of product categories from respiratory
and cough/cold to first aid and women's health. We are dedicated to providing our customers with the highest
quality generic pharmaceuticals.
Altana Pharma
Konstaz, Germany
ALTANA Pharma is a research-based company with dynamic growth. It employs over 8,800 people group-wide at
locations in Europe, North and Latin America, South Africa, Asia and Australia. ALTANA Pharma researches,
produces and markets medications in its core business of prescription medicines. It also manufactures and
markets diagnostic products for imaging technologies and self-medication products which are available without
prescription.
ALZA Corporation
ALZA Corporation, headquartered in Mountain View, California, is a research-based pharmaceutical company with
leading drug delivery technologies. ALZA applies its delivery technologies to develop pharmaceutical products with
enhanced therapeutic value for many of the world's leading pharmaceutical companies as well as for its own
portfolio. ALZA's strategy for building its commercial presence is to target specialty market opportunities, with a
focus on urology, oncology and central nervous system (CNS) products. By developing, acquiring and marketing
products in these areas, ALZA is establishing strong relationships with key physicians while providing a range of
therapies to treat the individual needs of patients.
Amgen, Inc.
Thousand Oaks, California
Amgen, the world's largest independent biotechnology company, was founded in Thousand Oaks, California in
1980 as AMGen (Applied Molecular Genetics). At the time, Amgen's corporate mission was to be the world leader
in discovering, developing and manufacturing cost-effective human therapeutics based on advances in cellular and
molecular biology. Currently, Amgen's Aspiration statement is to be the best human therapeutics company. We
will live the Amgen values and use science and innovation to dramatically impr ove people's lives. In-depth
knowledge developed through the utilization of state-of-the-art cellular and molecular biology enables Amgen
scientists to discover and develop both naturally occurring proteins and small molecules as potential human
therapeutics.
Amylin Pharmaceuticals, Inc.
9373 Towne Centre Drive
San Diego, California 92121
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative medicines to
improve the lives of people with metabolic diseases. The Company’s two late -stage, first-in-class diabetes product
candidates – SYMLIN® (pramlintide acetate) and exenatide (synthetic exendin -4) – are being developed to
address the global epidemic of diabetes. Amylin has a strategic alliance with Eli Lilly and Company for the codevelopment and global commercialization of exenatide, and an extended release formulation, exenatide LAR.
Building on its experience in the diabetes field, the Company is developing candida tes for cardiovascular disease
and obesity by utilizing its research experience with the metabolic properties common to all three conditions.
Andrx Corporation
Weston, Florida
Andrx Corporation is a specialty pharmaceutical company that applies its ten proprietary and patented oral
controlled-release drug delivery technologies and formulation skills to the research and develoment of
bioequivalent/generic (ANDA) and brand/proprietary (NDA) products. In it s generic program, Andrx primarily
develops bioequivalent versions of controlled-release brand products as well as difficult to replicate specialty,
niche or immediate release brand name pharmaceuticals. In its brand program, Andrx applies its oral control ledrelease technologies and formulation skills to develop improved versions of existing brand drugs, which will be
marketed as new brand pharmaceuticals. Andrx also markets and distributes, primarily to independent
pharmacies, pharmaceutical products manufactured by third parties.
Angiogene Pharmaceuticals Ltd.
Oxfordshire, United Kingdom
Angiogene is a drug discovery company targeting diseases involving active angiogenesis. The company was
originally formed in 1993 to exploit the expertise and intellectual property of the founding scientist, Dr. Graeme J.
Dougherty, in the areas of gene therapy and vascular biology. Angiogene established its U.K. Office in 1996 and
was registered in Scotland in 1997 as Angiogene Pharmaceuticals Ltd. The company's research is presently carried
out at laboratories in the U.K. and in North America. In 1998 Angiogene secured its first major partnership with a
large pharmaceutical company, licensing ANG453 to AstraZeneca. Renamed ZD6126, this compound is now in
Phase I.
Astellas Pharma Inc.
3-11, Nihonbashi-Honcho 2-Chome, Chuo-Ku
Tokyo, Japan
Manufacturing, marketing and import/export of pharmaceu ticals, quasi-drugs, foods and medical supplies and
systems, and home care business, etc. Astellas Pharma was formed from the merger of Fujisawa Pharmaceuticals
and Yamanouchi Pharmaceuticals in April 2005.
AstraZeneca Corporation
London, United Kingdom
AstraZeneca is one of the world's leading pharmaceutical companies. Backed by a strong research base and
extensive manufacturing and commercial skills, we provide innovative, effective medi cines that make a real
difference for patients in important areas of healthcare. We aim to be the first with new ideas and innovative in all
areas of our activity to create value for our customers, shareholders, employees and the communities in which we
work. AstraZeneca provides innovative, effective medicines designed to fight disease in important areas of medical
need: cancer, cardiovascular, central nervous system, gastrointestinal, infection, pain control and respiratory.
AtheroGenics, Inc.
8995 Westside Parkway
Alpharetta, Georgia 30004
AtheroGenics is an emerging pharmaceutical company focused on the discovery, development and
commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis,
rheumatoid arthritis and asthma. AtheroGenics has cultivated a drug discovery and development capability
directed toward rapidly creating and transporting small molecule therapeutics into the clinical testing ar ena to
ultimately establish the safety and efficacy of novel compounds that address serious unmet medical needs
AtheroGenics has assembled two synergistic technology platforms. Our proprietary v -protectantTM technology
platform has been the foundation of our discovery research efforts, and is the basis of our first three compounds,
currently in clinical development.
Athlon Pharmaceuticals, Inc.
Birmingham, Alabama
AthlonPharmaceuticals is an emerging pharmaceutical company that develops and markets quality
pharmaceuticals to physicians and pharmacies throughout the United States. Our professional, results -oriented
staff coupled with our sales strategies, have made us one of the fastest growing pharmac eutical companies in the
nation. Founded in 2001, we quickly grew to a company where today, our sales and marketing group covers over
thirty states and we are committed to having national coverage by the end of 2005.
AVANIR Pharmaceuticals
San Diego, California
AVANIR Pharmaceuticals is a drug discovery and development company that has a commercialized FDA -approved
product and a product in Phase III clinical trials. AVANIR is engaged in small molecule r esearch to develop
treatments for central nervous system disorders and inflammatory diseases. Through its subsidiary, Xenerex
Biosciences, AVANIR also develops human monoclonal antibodies for therapeutic applications.
Auxilium Pharmaceuticals
Malvern, Pennsylvania
Auxilium Pharmaceuticals (NASDAQ: AUXL) was founded in 1999 to develop and market pharmaceutical products
that focus on urology and sexual health. In addition to the development of follow -on products for androgen
replacement, the Company is pursuing product opportunities for other disorders. Auxilium is focused on helping
people live healthier lives. A significant number of the diseases and conditions that accompany aging can be
treated.
Aventis US
Bridgewater, New Jersey
Aventis is now part of the sanofi-aventis Group. The sanofi-aventis Group is the world’s 3rd largest
pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&D organization, sanofi-aventis
is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology,
diabetes, central nervous system, internal medicine, and vaccines.
AVI BioPharma (AVI)
One SW Columbia Suite 1105
Portland, Oregon 97258
AVI BioPharma develops therapeutic products for the treatment of life -threatening diseases using two technology
platforms: third-generation NEUGENE antisense drugs and cancer immunotherapy. AVI's lead NEUGENE antisense
compound is designed to target cardiovascular restenosis, cancer, polycystic kidney disease and other cell
proliferation disorders. In addition to targeting specific genes in the body, AVI's antiv iral program uses NEUGENE
antisense compounds to target single-stranded RNA viruses, including West Nile virus, SARS coronavirus,
calicivirus and hepatitis C. AVI's second technology, AVICINE®, is a therapeutic cancer vaccine with late -stage
trials planned for the treatment of pancreatic and colorectal cancer.
Axcan Pharma, Inc.
Mont-Saint-Hilaire, Québec, Canada
Axcan is a leading specialty pharmaceutical company within the field of gastroenterology in North America and
Europe. Axcan markets a broad line of pharmaceutical products used in the treatment of a variety of
gastrointestinal diseases and disorders. In addition to its marketing activities, Axcan carries out research and
development of products at an advanced stage of development that it acquires or licenses from third parties. By
combining its marketing expertise with its research and development experience, Axcan distinguishes itself from
specialty pharmaceutical companies that focus solely on distribution of products and offers potential licensors the
prospect of rapidly expanding the potential market for their products.
Axonyx Inc.
New York, New York
Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of
proprietary pharmaceutical compounds and new technologies useful in the diagnosis and treatment of Alzheimer's
Disease, human memory disorders and prion-based illnesses such as Mad Cow Disease.
3M Pharmaceuticals
St. Paul, Minnesota
3M Pharmaceuticals combines the agility of a small drug company with the reso urces of a major, multinational
corporation supported by 3M's annual R&D budget of over one billion dollars. Building upon an established 3M
research program in medicinal chemistry and combined with the acquisition of Riker Laboratories in 1970, 3M
Pharmaceuticals is known for its immune response modifier (IRM) product platform as well as respiratory and
cardiology drugs. In 1996, 3M Pharmaceuticals acquired the leading therapy for bacterial vaginosis enhancing 3M’s
presence in women’s health care.
Barr Laboratories, Inc.
2 Quaker Road, PO Box 2900
Pomona, New York 10970
Barr Laboratories, Inc. is a specialty pharmaceutical company engaged in developing, manufacturing and
marketing generic and proprietary pharmaceuticals.
Barrier Therapeutics, Inc.
100 Overlook Center 2nd Floor
Princeton, New Jersey 08540
Barrier Therapeutics, Inc. is a specialty pharmaceutical company focused on the development of novel
dermatological therapeutics. The privately held company was formed to develop and market dermatological
products based on intellectual property initially in -licensed from affiliates of Johnson & Johnson.
Bausch & Lomb
Rochester, New York
Bausch & Lomb is a global eye care company dedicated to helping consumers see, look, and feel better through
innovative technology and design. Founded in 1853, the company has annual revenues of approximately $2 billion
and employs approximately 12,000 people in 35 countries. Bausch & Lomb products are available in more than
100 countries around the world. Bausch & Lomb has three product lines: Vision Care, Surgical, and
Pharmaceuticals.
Baxter Healthcare Corporation
Deerfield, Illinois
Baxter Healthcare Corporation is the principal domestic operating subsidiary of Baxter International Inc. (NYSE:
BAX), a global health care company that, through its subsidiaries, provides critical therapies for people with life threatening conditions. Baxter's bioscience, medication delivery and renal products and services are used to treat
patients with some of the most challenging medical conditions, including cancer, hemophilia, immune deficiencies,
infectious diseases, kidney disease and trauma.
Bayer Pharmaceutical Division
Pittsburgh, Pennsylvania
Bayer Pharmaceuticals North America conducts business in three major areas of health care: prescription
medications, biological products, and biotechnology. Bayer is also one of the world's largest producers of
allergenic extracts, which are used by allergy professionals to desensitize patients suffering from various forms of
allergy.
Bayhill Therapeutics Inc.
3430 W. Bayshore Road Suite 201
Palo Alto, California 94303
Bayhill Therapeutics Inc. is focused on the translation of research into therapeutics for the treatment of
autoimmune diseases. The company has established a therapeutic platform of autoimmune modulators, in -licensed
from Stanford University, that address the broad market of Th1 mediated autoimmune diseases. The Company's
initial disease focus is multiple sclerosis, with its first product (BHT - 3009) entering Phase I/II studies in the first
quarter of 2004. In addition, the Company has a strong portfolio of product programs f ocused around individual
agents with demonstrated proof of concept as autoimmune modulators (AIM(TM)), as well as in the combination of
these modulators in a proprietary manner, AIMTx(TM).
Bentley Pharmaceuticals, Inc.
Bentley Park
Exeter, New Hampshire 03833
Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery
technologies and pharmaceutical products. Bentley's proprietary drug technologie s enhance or facilitate the
absorption of pharmaceutical compounds across various membranes. Bentley also manufactures and markets a
growing portfolio of branded and generic pharmaceuticals in Spain for the treatment of cardiovascular,
gastrointestinal, infectious and neurological diseases through its subsidiaries Laboratorios Belmac, Laboratorios
Davur and Laboratorios Rimafar.
Berlex Laboratories, Inc.
Montville, New Jersey
Berlex Laboratories, Inc., located in Wayne and Montville, NJ and Richmond, CA, is committed to bringing to the
market beneficial preventive, diagnostic and therapeutic medicines in the strategic fields of Dermatology,
Diagnostic Imaging, Female Healthcare, Therapeutics a nd Oncology. Driving our activities is a three -pronged
emphasis on recognizing and addressing marketplace needs, improving the quality of life for patients and building
strong relationships with the healthcare professionals who select and administer our ph armaceutical products.
Biogen Idec Inc.
Cambridge, Massachusetts
In November 2003, Biogen Idec Inc.(NASDAQ: BIIB) was formed from the merger of two of the world’s leading
biotechnology companies, Biogen, Inc. and IDEC Pharmaceuticals Corporation. This combination has resulted in a
fusion of complementary strengths in therapeutic focus, research and development capabilities, manufacturing
expertise, global infrastructure, and financial position. Biogen Idec intends to continue its growth through
discovery, development and commercialization of its own innovative products and through strategic alliances as
the partner-of-choice for biologics development, manufacturing and marketing. Biogen Idec is dedicated to
pursuing the creativity of science. The company’s products and development programs address a variety of key
medical needs in the areas of oncology, neurology, dermatology and rheumatology. nbsp; Merger of Biogen with
IDEC Pharmaceuticals finalized 11/12/2003. Email: [email protected].
Biovail Pharmaceuticals, Inc.
Morrisville, North Carolina
Biovail Pharmaceuticals Inc. markets Biovail and in-licensed products to physicians, pharmacists and hospitals
across the United States. It was created in 2000, through the acquisition of DJ Pharma Inc., providing Biovail with
an established network of U.S. sales professionals. Since its inception, Biovail Pharmaceuticals Inc. has enhanced
Biovail's presence in the U.S. marketplace through aggressive sales force expansion and the launch of new
pharmaceutical brands. Current products in its portfolio include Cedax®, Rondec®, Teveten®, Zovirax®,
Cardizem®, Vasotec® and the Vaseretic® product line. This portfolio will be expanded through product licensing
and acquisitions, as well as the addition of branded products developed by Biovail. Biovail Corporation
(headquartered in Mississauga, Ontario, CANADA) is a full -service pharmaceutical company, engaged in the
formulation, clinical testing, registration, manufacturing, sale and promotion of pharmaceutical products by
utilizing advanced oral controlled-release and FlashDose® technologies.
Boehringer Ingelheim Corporation
Ridgefield, Connecticut
Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. Boehringer
Ingelheim corporation is a family-owned company. It is owned by a committee of private shareholders dedicated
to the long term interests of the corporation´s stakeholders, including its customers, employees and the
communities within which it operates. This distinctively independent structure makes it more poss ible to operate
according to long term strategies rather than short term priorities. Best selling Prescription Medicines products:
Combivent®, Flomax®, Atrovent®, Catapres®, Mobic®
Boston Life Sciences, Inc.
Boston, Massachusetts
Boston Life Sciences, Inc. (BLSI) is a development stage biotechnology company engaged in the research and
development of novel therapeutic and diagnostic solutions for central nervous system diseases (CNS) and cancer.
BLSI's products in development include: ALTROPANE® and FLUORATEC(TM) radioimaging agents for the diagnosis
of PD and ADHD; Troponin I, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1
and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders; novel therapies for the
treatment of PD and ADHD; and transcription factors that may control the expression of molecules associated with
autoimmune disease and allergies.
Bristol-Myers Squibb Company
New York, New York
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to
extend and enhance human life. At Bristol-Myers Squibb, our mission is to extend and enhance human life by
providing the highest-quality health care products and services. Our medicines are making a difference in the lives
of millions of customers across the globe. And by living our mission and growin g our company for well over a
century, we are making a difference in the lives of our shareholders, employees and neighbors as well.
Bradley Pharmaceuticals, Inc.
Fairfield, New Jersey
Bradley Pharmaceuticals, Inc. is a specialty pharmaceutical company that provides therapies to niche physician
specialties in the U.S. and 38 international markets. The Company's Doak Dermatologics subsidiary delivers
dermatology and podiatry therapies, while the Kenwood Therapeutics division provides gastroenterology and
internal medicine brands
Cambridge Antibody Technology (CAT)
Cambridge, United Kingdom
Cambridge Antibody Technology (CAT) is a world leading company in the discovery and development of human
monoclonal antibody therapeutics. Using its pioneering technologies, CAT has developed an impressive pipeline of
novel human monoclonal antibody drugs. Six of these are currently at various stage s of clinical trials, with a
seventh (D2E7) having been submitted for regulatory review, following the completion of Phase III trials for the
treatment of rheumatoid arthritis. The Company's business is driven from a proprietary platform of phage display
technologies. To maximise commercial opportunities, CAT has built an array of strategic collaborations with
leading pharmaceutical and biotechnology companies worldwide.
Cardinal Health
Dublin, Ohio
Cardinal Health, Inc. provides products and services to health care providers and manufacturers. The company
operates in four segments: Pharmaceutical Distribution and Provider Services, Medical Products and Services,
Pharmaceutical Technologies and Services, and Clinical Technologies and Services. The Pharmaceutical
Distribution and Provider Services segment distributes pharmaceuticals, health care products, and other items in
the United States. It also operates a distribution network to offer branded and gen eric pharmaceutical products in
the United Kingdom; provides distribution and support services; and operates and franchises apothecary -style
retail pharmacies.
Celgene Corporation
Warren, New Jersey
Celgene Corporation is a specialty pharmaceutical Company engaged in the development and commercialization of
human pharmaceuticals and agrochemicals. It employs two broad technology platforms: (i) small molecule
immunotherapeutic compound development and (ii) biocatalytic chiral chemistry. The focus of the immunology
program is the development of small molecule pharmaceuticals that selectively regulate Tumor Necrosis Factor
alpha (TNF-alpha), a protein whose overproduction has been linked to many chronic in flammatory and
immunological diseases. The company's lead compound is THALOMID® which was approved in 1998. THALOMID
(thalidomide) which is currently indicated for the acute treatment of the cutaneous manifestations of moderate to
severe erythema nodosum leprosum (ENL). THALOMID (thalidomide) is not indicated as monotherapy for such ENL
treatment in the presence of moderate to severe neuritis. THALOMID (thalidomide) is also indicated as
maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. Celgene
has further applied its expertise in small molecule chemistry to develop novel and proprietary thalidomide
analogues, called IMiDs™(Immunomodulatory Drugs) as well as a class of proprietary immunotherapeutic
compounds called SelCIDs™ (Selective Cytokine Inhibitory Drugs) both of which are highly specific modulators of
TNF-alpha.
Cell Therapeutics, Inc.
Seattle, Washington
CTI is committed to developing, acquiring, and commercializing innovative treatments for cancer. In our pursuit of
making cancer more treatable, the Company is developing a diversified portfolio of oncology products focused on
identifying new, less toxic, and more effective cancer therapies.
Cellegy Pharmaceuticals
South San Francisco, California
Cellegy Pharmaceuticals is a specialty biopharmaceutical company engaged in the development and
commercialization of prescription drugs with primary focus in the areas of gastroenterology, sexual dysfunction
and women's health care. Cellegy has developed expertise in the use of nitroglycerin ointment and nitric oxide
donors to address a number of serious conditions. Cellegesic(TM) ointment for the treatment of anal fissures and
hemorrhoids is currently awaiting FDA protocol approval of a confirmatory Phase III clinical trial to treat the
severe pain associated with chronic anal fissures. The Company is also conducting clinical trial s using Cellegesic to
treat hemorrhoids. Other nitroglycerin based product candidates, in earlier clinical development, are targeting
conditions including female sexual dysfunction, Raynaud's disease and prostate cancer. Cellegy is also developing
a second testosterone product, Tostrelle(TM) Gel for the treatment of female sexual dysfunction. Tostrelle is
undergoing a phase II / III clinical trial in the United States and has generated significant interest from potential
partners and the medical community.
CeMines, Inc.
La Jolla, California
CeMines(TM) is a new-generation biotechnology company that applies the principles of gene regulation in
development of early-stage diagnostics and targeted therapeutics for cancers and other diseases, based on the
Company's patent-pending, proprietary biomarker technology known as CeMines Molecular FingerPrinting(TM).
CeMines™ has developed its breakthrough Molecular FingerPrinting™ blood test for the early -detection and
optimized treatment of a variety of cancers and other immune diseases. Based on monitoring disease -specific
molecular changes in gene regulatory machinery, CeMines™ believes that its minimally invasive diagnostic tests
will provide accurate, early detection of most widespread cancers --including lung, breast, prostate and
gastrointestinal - and can provide critical information in optimal treatment modalities.
Centocor, Inc.
Building on our leadership position in monoclonal antibody technology, Centocor creates, acquires and markets
unique biopharmaceutical therapies. Our innovative products focus on the management of three major disease
areas; cardiovascular, immunologic disorders and cancer. Centocor is proud to be part of the Johnson & Johnson
family of companies.
Cephalon, Inc.
West Chester, Pennsylvania
Cephalon seeks to discover, develop and market innovative product s to treat neurological and sleep disorders,
cancer, and pain. The company is committed to providing patients and the medical community with novel
therapies to treat unmet medical conditions through its proprietary research programs and by acquiring promis ing
products for clinical development and commercial sale. Our success is supported by a proven strategy of
marketing high-growth, innovative products, building our worldwide marketing and distribution channels, and
investing in research and development of unique compounds that may change the course of a disease. An
international biopharmaceutical company headquartered in West Chester, Pennsylvania, with offices and
manufacturing facilities in Salt Lake City, Utah. Cephalon's major European offices are loca ted in Guildford,
England, and at Laboratoire L. Lafon, in Maisons-Alfort, France. Founded in 1987 by Frank Baldino, Jr., Ph.D. Co founders: James Kauer, Ph.D. and Michael Lewis, Ph.D. Three growth products marketed in the United States and
more than twenty products marketed globally. Revenue from product sales in 2001 was $226.1 million vs $91.6
million in 2000. Approximately 1,200 employees in the U.S. and Europe. Merger with CIMA LABS announced
11/03/03.
Chiron Corporation
Emeryville, California
Chiron Corporation is a global pharmaceutical company that leverages a diverse business model to develop and
commercialize high-value products that make a difference in people's lives. The company has a strate gic focus on
cancer and infectious disease. Chiron applies its advanced understanding of the biology of cancer and infectious
disease to develop products from its platforms in proteins, small molecules and vaccines. The company
commercializes its products through three business units: vaccines, blood testing, and biopharmaceuticals.
Chugai Pharma USA
Chugai Pharma USA, LLC discovers and develops therapeutic products that tre at cardiovascular diseases, cancer,
plus gastrointestinal and joint diseases. Our 72,000-sq. ft. facility in San Diego, California houses molecular
biology, biochemistry, as well as high throughput screening, medicinal chemistry laboratories, and a large c linical
development team. In line with our overall mission, Chugai Pharma USA is developing the infrastructure required
to commercialize therapeutic drug products in the US. At CPUSA we strive to maintain a working environment that
offers our employees ample opportunities and resources to realize their full potential and to advance within the
organization.
CIMA Labs Inc. (CIMA)
10000 Valley View Road
Eden Prairie, Minnesota 55344
CIMA develops and manufactures prescription and over-the-counter products based upon its proprietary, orally
disintegrating drug delivery technologies, OraSolv® and DuraSolv®. Based on these technologies, an active drug
ingredient, which the company frequently taste-masks, is formulated into a new, orally disintegrating dosage form
that dissolves quickly in the mouth without chewing or the need for water. CIMA's business involves a dual
operating strategy. The company develops and manufactures orally disintegrating versions of drugs for
pharmaceutical company partners for whom CIMA currently produces three branded prescription pharmaceuticals
and three over-the-counter brands. CIMA is also developing proprietary products utilizing its orally disintegrating
technologies, as well as its new OraVescent® enhanced absorption, transmucosal drug delivery technology. NOTE:
Merger with aaiPharma originally announced 8/05/2003, was terminated 11/03/2003. Merger with Cephalon, Inc.
announced 11/03/03.
CollaGenex Pharmaceuticals, Inc.
Newton, Pennsylvania
CollaGenex Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on providing innovative medical
therapies for dermatological diseases. CollaGenex is developing dermatol ogical applications of its proprietary
IMPACS™ technology. Oracea™ has completed Phase III clinical trials for the treatment of the inflammatory
lesions of rosacea. A new Drug Application (NDA) for Oracea was submitted to the FDA on July 31, 2005.
Incyclinide formerly known as Col-3 is in Phase II clinical trials for the treatment of acne.
Confluent Surgical, Inc.
Waltham, Massachusetts
Confluent is a private medical device company founded in August 1998, that is pioneering the development of In situ-polymerized Biomaterials. These materials have almost universal applications across minimally invasive
surgery, because they allow the safe, simple, and rapid, formation of customized imp lants at the site of disease.
This process can take place rapidly when two aqueous solutions of molecularly designed synthetic polymers mix
together. Confluent's vision is to address unmet needs in surgery and interventional procedures using its
technology platform of in situ polymerization.
Columbia Laboratories, Inc.
Livingston, New Jersey
Columbia Laboratories, Inc. develops and commercializes pharmaceutical products that use our proprietary drug
delivery technologies. We currently promote six products to select U.S. audiences, and have forged partnerships
to address additional U.S. audiences as well as foreign markets. This dual revenue stream provides us with a solid
base business from the sale of partnered products with upside potential from promoted products driven by our
sales force.
Connetics Corporation
Palo Alto, California
Connetics Corporation is a specialty pharmaceutical company focused on the development and commercialization
of innovative therapeutics for the dermatology market. The Company's marketed products are OLUX(R) (clobetasol
propionate) Foam, 0.05% and Luxiq(R) (betamethasone valerate) Foam, 0.12%. The Comp any also is developing
Extina(TM), a foam formulation of the antifungal drug ketoconazole, and Actiza(TM), a foam formulation of
clindamycin for treating acne. Connetics also recently in-licensed Velac(R) gel, a combination acne therapy. These
formulations aim to improve the management of dermatological diseases, provide significant product
differentiation, and extend product life cycles.
Cook Surgical
Bloomington, Indiana
Cook Surgical markets medical biomaterials from acellular natural tissues through its tissue engineered products
group. In addition, the company's growing team of medical device engineering and development specialists works
with leading researchers at hospitals and university medical centers around the world to develop, test and perfect
important new diagnostic and interventional medical products.
Corautus Genetics
6555 Nancy Ridge Drive
San Diego, California 92121
Corautus Genetics Inc. is a biopharmaceutical company dedicated to the development of innovative gene therapy
products for the treatment of cardiovascular disease. Corautus Genetics was formed by the merger of Vascular
Genetics Inc. with GenStar Therapeutics Corporation to capitalize on the complementary strengths of these
companies to accelerate the development of a later stage product for cardiovascular disease. Corautus Genetics'
core technology is based upon gene therapy for "therapeutic angiogene sis." In this approach, the injection of
genes for vascular growth factors stimulate the formation of new blood vessels to help compensate for reduced
blood flow due to advanced cardiovascular disease. The focus of the company's efforts will be the clinica l
development of gene therapy products using a vascular growth factor gene (Vascular Endothelial Growth Factor 2
or "VEGF-2") for the treatment of severe cardiovascular disease.
Corixa Corporation
Seattle, Washington
Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune disease,
cancer and infectious disease by understanding and directing the immune system. Corixa is focused on
immunotherapeutic products and has a broad technology platform enabling both full y integrated vaccine design
and the use of its separate, proprietary product components on a standalone basis. Corixa currently has 16
programs in clinical development and 22 programs in preclinical development, including its most advanced product
candidate, BEXXAR®, a monoclonal antibody conjugated to a radioisotope.
Corus Pharma Inc.
2025 1st Avenue Ste 800
Seattle, Washington 98121
Corus Pharma seeks to develop drugs to treat unme t needs in the infectious diseases and respiratory areas. The
company's core competencies reside in the identification of drug candidates, rapid clinical development and FDA
approval of its products. Target development candidates will be identified through a combination of internal ideas,
academic research and a search of projects in other organizations.
Corvas International, Inc.
Corvas International, Inc. is a biopharmaceutical company focused on the development of new biotherape utics
that address large medical markets, including cancer and cardiovascular disease. rNAPc2, Corvas' cardiovascular
drug candidate currently in Phase II clinical trials, is a novel anticoagulant intended for the treatment of people
affected by acute coronary syndromes, which include unstable angina and non-ST-segment elevation myocardial
infarction. Corvas' cancer research programs are focused on the development of new biotherapies, including
monoclonal antibodies and synthetic prodrugs, that target serine proteases associated with the growth and spread
of cancerous tumors. Note: Merger with Dendreon Corporation approved by Corvas shareholders on 7/28/2003.
Critical Therapeutics, Inc.
Lexington, Massachusetts
Critical Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and
commercialization of products for respiratory, inflammatory and critical care diseases. The Company owns
worldwide rights to the asthma drug ZYFLO® (zileuton tablets), as well as other formulations of zileuton. ZYFLO is
the only 5-lipoxygenase inhibitor approved for marketing by the U.S. Food and Drug Administration and is
indicated for the prevention and chronic treatment of asthma in adults and children 12 years of age and older. The
Company’s commercialization efforts for ZYFLO are carried out by its 80 -person specialty sales force.
Cubist Pharmaceuticals, Inc.
Cubist Pharmaceuticals, Inc. is focused on becoming a global leader in the research, development and
commercialization of novel pharmaceuticals to combat serious and life -threatening infections. Cubist is evaluating
the safety and efficacy of Cidecin(R) (daptomycin for injection) in the EDGE(TM) (Evaluation of Daptomycin
against Gram-positive Entities) clinical trial program and has broadened its pipeline to include multiple pre -clinical
drug candidates, including an oral version of ceftriaxone (OCTX), a broad-spectrum cephalosporin antibiotic, and
CAB-175, a next generation cephalosporin antibiotic with demonstrated in vitro activity against methicillin resistant Staphylococcus aureus (MRSA). The company is engaged in a strategic partnership with Novart is Pharma
AG for the discovery and development of novel antiinfectives.
CV Therapeutics, Inc. (CVT)
3172 Porter Drive
Palo Alto, California 94304
CV Therapeutics is a biopharmaceutical company focused on applying molecular cardiology to the discovery,
development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.
CV Therapeutics currently has four compounds in clinical trials. If approved by the FD A, Ranexa would represent
the first new class of anti-anginal therapy in more than 20 years. Tecadenoson, an A1-adenosine receptor agonist,
is being developed for the potential reduction of rapid heart rate during atrial arrhythmias. CVT -3146, a selective
A2A-adenosine receptor agonist, is being developed for potential use as a pharmacologic stress agent in cardiac
perfusion imaging studies. Adentri(TM), an A1-adenosine receptor antagonist for the potential treatment of acute
and chronic congestive heart failure, is licensed to Biogen, Inc.
Cyclacel Limited
Dundee Technopole
Dundee, United Kingdom DD1 5JJ
Cyclacel is a biopharmaceutical company that designs and develops small molecule drugs that act on key cell cycle
regulators to stop uncontrolled cell division in cancer and other diseases involving abnormal cell proliferation.
Cyclacel's discovery engines integrate cell cycle biology expertise with a large library of gene -based targets,
state-of-the-art RNAi functional genomics, chemogenomics and clinical biomarker technologies to rapidly deliver
new drugs.
Cytogen Corporation
Princeton, New Jersey
Cytogen Corporation is a product-driven, oncology-focused biopharmaceutical company. Cytogen markets several
products through its in- house oncology sales force: ProstaScint(R) (a monoclonal antibody -based imaging agent
used to image the extent and spread of prostate cancer); BrachySeed(TM) I -125 and BrachySeed(TM) Pd-103 (two
uniquely designed, next- generation radioactive seed implants for the treatment of localized prostate cancer); and
NMP22(R) BladderChek(TM) (a highly accurate and convenient antibody-based point-of-care staging test for
bladder cancer detection). Cytogen has also developed Quadramet(R), a skeletal targeting therapeutic
radiopharmaceutical for the relief of bone pain in prostate and other types of cancer, for which the company
receives royalties on product sales through Berlex Laboratories, the U.S. affiliate of Schering AG Germany, which
markets the product in the United States.
Daiichi Sankyo Co., Ltd.
Tokyo, Japan
DAIICHI SANKYO COMPANY, LIMITED has taken the first steps toward challenging the world market by becoming a
Japan-Based Global Pharma Innovator on September 28, 2005. We continue to provide innovative pharmaceuticals
to meet the medical needs of people all over the globe.
Dendreon Corporation
Seattle, Washington
Dendreon Corporation is a biotechnology company developing targeted therapies for cancer. The Company's lead
investigational product candidate, Provenge®, is a cancer immunothe rapy undergoing a pivotal Phase 3 clinical
trial for the potential treatment of androgen independent prostate cancer. In addition to its therapeutic vaccines
in clinical and preclinical development for a variety of cancers, Dendreon's product pipeline also includes
monoclonal antibody and small molecule product candidates. Dendreon has established important research and
development alliances with industry leaders Genentech, Inc. and Kirin Brewery Co., Ltd. Note: Acquisition of
Corvas International approved by Dendreon shareholders on 7/29/2003.
Dermik Laboratories (A business of Sanofi-Aventis)
With nearly 60 years of experience in dermatology, Dermik has a proud heritage of nurturing products fro m
inception to market leadership. As a leading global dermatology company, our portfolio includes therapeutic and
aesthetic products that treat a range of conditions, from acne to HIV-associated facial lipoatrophy. Dermik's goal
is to produce and pursue innovative products that improve the lives of patients. Our capabilities as a subsidiary of
the sanofi-aventis Group include state-of-the-art discovery and development programs, formulation expertise,
large-scale manufacturing operations, skilled sales and marketing personnel, and a strong dermatology sales
force.
diaDexus, Inc.
diaDexus, Inc., a privately held biotechnology company, is focused on the discovery, developme nt and
commercialization of novel, patent-protected diagnostic and therapeutic products with high clinical value.
diaDexus utilizes genomics and bioinformatics to identify numerous disease -associated molecular targets.
Dey, Inc.
Napa, California
Dey, Inc. develops, manufactures and markets prescription drug products for the treatment of respiratory
diseases and related allergies. The company manufactures sterile, unit dose inhalation solution pr oducts,
manufactured using aseptic form-fill-seal technology. Products of the company is marketed to large institutional
purchasers, wholesalers, group purchasing organizations, chain pharmacies, health maintenance organizations and
home health care organizations. During the year, the company transferred the assets and certain liabilities of its
hypothyroid product business at book value to a newly-formed entity, EM Pharma, Inc. In June 1998, the company
has changed its name from Dey Laboratories, Inc.
DOR BioPharma, Inc.
1691 Michigan Ave Suite 435
Miami, Florida 33139
DOR BioPharma, Inc. is a biopharmaceutical company focused on the development of biodefense vaccines and
therapeutics for areas of unmet medical needs. Through its BioDefense Division, DOR is developing bioengineered
vaccines designed to protect against the deadly effects of ricin toxin and botulinum toxin. DOR's lead therapeutic
product, orBec® (an oral formulation of becl omethasone dipropionate), is a potent, locally-acting corticosteroid
being developed to treat inflammation in the mucosal lining of the intestine and stomach that can occur following
allogeneic bone marrow and stem cell transplants.
DOV Pharmaceutical Inc.
Hackensack, New Jersey
DOV is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of
novel drug candidates for central nervous system, cardiovascular and urological disorders. The Company has five
product candidates in clinical trials addressing therapeutic indications with significant unmet needs. In addition to
bicifadine for pain, those candidates address insomnia (indiplon, under license to Neurocr ine and in Phase III
development), anxiety (ocinaplon, joint ventured with Elan), angina and hypertension (joint development with
Biovail) and depression (DOV 216-303, being developed in-house).
Dynavax Technologies
717 Potter Street, Suite 100
Berkeley , California 94710
Dynavax Technologies is a biopharmaceutical company developing innovative products for treating and preventing
allergy, inflammation-mediated diseases, infectious diseases and cancer. The company's lead products are based
on ImmunoStimulatory Sequences (ISS), short DNA sequences that enhance the ability of the immune system to
fight disease and control chronic inflammation. Because ISS target the cause of many diseases - a faulty immune
response - they represent a potential breakthrough in the treatment of immune -related disorders. ISS therapy is
expected to be more effective, longer lasting, safer and more convenient than current treatments. With four ISS based product candidates currently in clinical trials, Dynavax has established a leadership position in the research
and development of novel therapies for a range of major immune-related disorders.
ECR Pharmaceticals
Richmond, Virginia
ECR PHARMACEUTICALS markets both prescription and consumer products (which may be purchased without a
prescription). Current therapeutic categories include oral analgesics, topical arthritis pain relievers, cough and
cold medications, as well as products for seasonal allergies and contact dermatitis. Products are marketed
nationwide, with most of ECR’s sales staff currently located in the southeastern and southwestern United States.
Eisai, Inc.
Teaneck, New Jersey
Eisai selects products for worldwide development that bring value to patients and their families and meet
treatment needs. Worldwide, Eisai Co., Ltd. and its affiliates spend more than 15% of its revenue on research and
development. Areas of study include immunology, endocrinology, gastroenterology, neurology, cardiology,
pulmonology and oncology.
Elan Corporation, PLC
Dublin, Ireland
Elan Corporation, plc (Elan) began in 1969 with a vision: to approach the challenge of drug delivery from an
entirely new angle—that of controlled absorption of a drug by the patient’s body. Over the years, Elan transitioned
to become a world leader in drug delivery and specialty pharmaceuticals . Today, Elan has become a fully
integrated biopharmaceutical company, pioneering exciting new research and development in Alzheimer’s disease,
Parkinson’s disease, multiple sclerosis, cancer, pain management and autoimmune diseases. It is focused on the
discovery, development, and marketing of products and services in neurology, pain management, oncology,
infectious disease and dermatology and on the development and commercialization of products using its extensive
range of proprietary drug delivery technologies.
Encysive Pharmaceuticals
6700 West Loop, 4th Floor
Bellaire, Texas 77401
Encysive Pharmaceuticals is a pharmaceutical company that discovers, develops and commercializes small
molecule drugs aimed at cardiovascular and inflammatory diseases. Our research strategy focuses on the vascular
endothelium, because of its importance in the evolution of a number of serious diseases for which current
therapies are inadequate. Today, we are capitalizing on the approval of our first product, Argatroban, the R&D
assets embedded in a full pipeline of promising drug candidates, and our growing clinical and business expertise
to make the transition to a successful commercial operation. [Formerly Texas Biotech nology, name changed May
2003].
Endo Pharmaceuticals Inc.
Chadds Ford, Pennsylvania
A wholly owned subsidiary of Endo Pharmaceuticals Holdings (Nasdaq: ENDP, ENDPW), Endo Pharmaceuticals is a
fully integrated specialty pharmaceutical company with market leadership in pain management products. The
company researches, develops, produces and markets a broad product offering of both branded and generic
pharmaceuticals, meeting the needs of healthcare professi onals and consumers alike.
Enzo Biochem, Inc.
New York, New York
A leading biotechnology company engaged in the research, development, manufacturing and marketing of
innovative health care products. Its three business subsidiaries are focused on early diagnosis, prevention and
therapeutic treatment of disease. The company has concentrated on the development of enabling technologies in
the areas of gene modification and gene regulation. In focusing its efforts in these areas, and in achieving patent
protection for its technologies, Enzo has established the basis for a broad category of novel products, both
diagnostic and therapeutic.
Enzon Pharmaceuticals, Inc.
Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and
commercialization of therapeutics to treat life-threatening diseases. The company has developed or acquired a
number of marketed products, including ABELCET, which is marketed in North America by Enzon, and PEG INTRON, marketed by Schering-Plough. Enzon’s product-focused strategy includes an extensive drug development
program that leverages the Company’s PEG modificati on and single-chain antibody (SCA®) technologies. Internal
research and development efforts are complemented by strategic transactions that provide access to additional
products, projects, and technologies. Enzon has several drug candidates in various stag es of development,
independently and with partners.
Eon Labs, Inc.
Laurelton, New York
Eon Labs, Inc. is a generic pharmaceutical company engaged in developing, licensing, manufac turing, selling and
distributing a broad range of prescription pharmaceutical products. An industry leader in obtaining Abbreviated
New Drug Application, or ANDA, approvals from the U.S. Food and Drug Administration for new generic
pharmaceutical products, Eon Labs' product line consists of nearly 250 products from more than 100 medications.
Eon Labs' experienced management team utilizes an integrated approach to select and develop generic
pharmaceutical products in both niche and high volume markets in order to be the first generic alternative to
market and to obtain favorable market share. Eon Labs focuses on drugs in a broad range of solid oral dosage
forms, utilizing both immediate and sustained release delivery.
ESP Pharma
Fremont, California
Developing and commercializing innovative therapies for serious or life -threatening illnesses — this is what PDL
BioPharma is all about. With a unique focus on the acute care, hospital -based setting, our research, development
and commercial teams are working to bring new therapies to physicians and patients that we hope will improve
and save lives. Today, our commercial products — Cardene I.V., Retavase and IV Busulfex — are helping patients
with serious medical illnesses, while our research and development teams strive to bring important innovative new
therapies to the forefront of tomorrow's patient care.
Esperion Therapeutics, Inc.
3621 South State Street
Ann Arbor, Michigan 48108
Esperion Therapeutics, Inc., is a biopharmaceutical company dedicated to the discovery, development and
commercialization of a novel class of therapies to treat cardiovascular and metabolic diseases, including
atherosclerosis, as they relate to high density lipoprotein cholesterol, “HDL -C”, also known as the “good”
cholesterol. The technology platform for Esperion is based upon the Reverse Lipid Transport (RLT) pathway. The
RLT pathway is responsible for removing excess cholesterol and other lipids from arterial walls and other tissues
for transport to the liver and elimination from the body. The Company’s product candidates work by stimulating
the RLT pathway through the enhancement of key HDL properties, which may result in improved vascular
structure and function. Esperion is focusing its efforts on developing both acute and chronic therapies for
cardiovascular and metabolic diseases.
Esprit Pharma
East Brunswick, New Jersey
Esprit Pharma is a forward thinking company committed to improving patient wellness within the genitourinary
and women’s healthcare fields. Led by experienced management, Esprit actively pursues its buy, build, search &
develop strategy of acquiring, developing, and marketing medicines serving the unique needs of these physician
specialties, supported by product expertise, medical education, and customer service.
EXACT Sciences Corporation
100 Campus Drive
Marlborough, Massachusetts 01752
EXACT Sciences Corporation is an applied genomics company located in Maynard, MA. Founded in 1995, the
company's mission is to play a leading role in the eradication of common cancers by applyi ng advances in the field
of genomics to facilitate early detection of disease. EXACT Sciences believes its proprietary, genomics -based
technologies will revolutionize the early detection of colorectal and other common cancers. EXACT Sciences
believes that widespread and periodic application of these non-invasive technologies will reduce the mortality,
morbidity and healthcare costs associated with these diseases.
Eyetech Pharmaceuticals
Melville, New York
OSI Pharmaceuticals is committed to “shaping medicines and changing lives” by discovering, developing and
commercializing high-quality and novel pharmaceutical products that extend life or improve the quality of life for
patients with cancer, eye diseases and diabetes.
Eli Lilly and Company
Indianapolis, Indiana
Eli Lilly and Company creates and delivers innovative medicines that enable people to live longer, healthier and
more active lives. Lilly products treat depression, schizophrenia, diabetes, cancer, osteoporosis and many other
diseases. They create value for patients, health-care providers and payers, and reduce the cost of disease.
FibroGen Inc.
FibroGen has developed the only commercially viable method known to produce human collagen and human
gelatin in recombinant systems. FibroGen will exploit this technology by becoming both a bulk product supplier for
the pharmaceutical and medical device industries as well as a developer and commercializer of injectable
products, wound management products, and gelatin stabilizers. FibroGen's corporate collaborations include a
partnership with Taisho Pharmaceutical Company of Japan to discover and develop human monoclonal antibody
therapeutics for renal fibrosis and chronic transplant rejection.
Ferndale Laboratories, Inc.
Ferndale, Michigan
First Horizon Pharmaceutical Corporation
Alpharetta, Georgia
First Horizon Pharmaceutical Corporation is a specialty pharmaceutical Company that markets prescription
products in four therapeutic areas: cardi ology, obstetrics and gynecology, pediatrics and gastroenterology. The
Company has a portfolio that includes 17 branded prescription products of which 7 are actively promoted to high prescribing physicians through its nationwide marketing and sales force.
Ferring Pharmaceuticals
Switzerland, Lausanne
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and
marketing innovative products in the fields of urology, gynaecology & obstetrics, gastroenterology and
endocrinology. The company’s research activities and products are connected by a common thread focused on the
provision of tailored treatments that work on the body’s own terms to enable doctors comb at numerous diseases
and medical conditions.
Fujisawa Healthcare, Inc.
Deerfield, Illinois
Fujisawa Healthcare, Inc., headquartered in Deerfield, Illinois is a subsidiary of Fujisawa Pharmaceutica l
Company, Ltd., based in Osaka, Japan. Fujisawa Pharmaceutical Co., Ltd., founded in 1894, is a leading
pharmaceutical manufacturer and is actively developing its international operations in North America, Europe and
Asia. Being the world's largest pharmaceutical market, the United States naturally occupies a preeminent position
at the core of Fujisawa's international strategy.
First Horizon Pharmaceutical Corporaion
Alpharetta, Georgia
First Horizon Pharmaceutical Corp, NASDAQ: FHRX, founded in 1992, headquartered in Atlanta, GA, is a
pharmaceutical company specializing in sales, marketing and the development of branded prescription products
focused on Cardiovascular/Metabolic and Women's health. The Company's Cardiovascular/Metabolic products treat
patients with high cholesterol, hypertension, high triglycerides, unstable angina and type 2 diabetes, and its
Women's Health products improve the health and well-being of mothers and their babies. The Company's success
is based on its business platform - an Entrepreneurial Spirit, Innovation, Speed of Execution, Simplicity and
Teamwork. By placing the needs of patients first, improving health and quality of life, and ac ting in accordance
with our values, the Company will continue to achieve success and realize its vision.
Forest Laboratories, Inc.
New York, New York
Forest identifies, develops and delivers pharmaceutical products that make a difference in people's lives. Lexapro
is one of the fastest-growing SSRI antidepressant in the United States. Benicar has become an important
treatment option for hypertension. Namenda is the first approved therapy in the United States for those with
moderate or severe Alzheimer's disease.
GelTex Pharmaceuticals, Inc. (a Genzyme General Business)
GelTex’s first product, Renagel® brand sevelamer hydrochloride , was granted marketing approval by the U.S.
Food and Drug Administration (FDA) in October 1998 for the reduction of serum phosphorus in hemodialysis
patients. In addition, WelChol(TM) brand colesevelam hydrochloride was granted marketing approval by the F DA
in May 2000, for the treatment of hypercholesterolemia, a condition characterized by undesirably high blood
cholesterol levels. (WelChol is a trademark of Sankyo Pharma Inc., our partner for commercializing WelChol)
Gen-Probe Incorporated
GEN-PROBE currently markets several product lines, including the PACE® 2 System, the GEN -PROBE®
AMPLIFIED™ Direct Tests, and the AccuProbe® System. Other products are currently under develop ment or
awaiting FDA approval. GEN-PROBE products continue to set the standard for DNA probe technology in the
diagnostic industry, with assays for sexually transmitted diseases, microbial infectious diseases, and culture
identification. In addition, we offer a full line of supporting instrumentation.
Galderma
Fort Worth, Texas
Since the creation of Galderma in 1981 as a joint venture between Nestlé and L'Oréal, all of our resources have
been channelled in one direction: to provide innovative therapeutic solutions that meet the needs of dermatology
patients and physicians. Our experience has taught us that the effects of skin conditions reach much deeper than
the skin itself. By treating and caring for skin, we help people improve their quality of life. To achieve this, we pay
special attention not only to the efficacy of our products, but also to their cosmetic qualities and galenic
properties. This is what makes our products appealing to patients and dr ives our scientists to explore new areas in
dermatological innovation.
Genaera Corporation
5110 Campus Drive
Plymouth Meeting, Pennsylvania 19462
Genaera Corporation is a biopharmaceutical company committed to developing medicines for serious diseases
from genomics and natural products. Research and development efforts are focused on anti -angiogenesis and
respiratory diseases. Genaera has three products in development addressing substantial unmet medic al needs in
major pharmaceutical markets. These include squalamine, an anti -angiogenic treatment for eye disease and
cancer; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; and
LOMUCIN(TM), a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of
chronic respiratory disease.
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, Connecticut 06511
Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the
development of personalized medicines and DNA-based diagnostics. Genaissance markets its technology, clinical
development skills and pharmacogenetic services to the pharmaceutical industry as a complete solution for
improving the development, marketing and prescribing of drugs. Genaissance has agreements with major
pharmaceutical, diagnostic and biotechnology companies.
Genentech, Inc.
Genentech, the founder of the biotechnology industry, is a company with a quarter -century track record of
delivering on the promise of biotechnology. Today, Genentech is among the world's leading biotech companies -with 10 protein-based products on the market for serious or life-threatening medical conditions. Genentech's
product pipeline includes approximately 20 projects that focus primarily on oncology, cardiovascular disea se and
immunological disease. With its world-renowned research organization, unparalleled development and
manufacturing capabilities, highly sophisticated commercial organization, and close to 5,000 competent, creative
and enthusiastic employees, Genentech continues to transform the possibilities of biotechnology into improved
realities for patients. For more general information about the company, visit our corporate overview section.
Genesis Bio-Pharmaceuticals
Hackensack, New Jersey
Genesis Bio-Pharmaceuticals was established in 1990 as a Pharmaceutical marketing and distribution organization
specializing in providing plasma derivative products, transplant products, vaccines and specialty surgical products
as well as unique distribution services to hospitals, clinics, home IV therapy centers, pharmacies and physician
offices. Genesis Bio-Pharmaceuticals has relationships with most major plasma derivative manufacturers as well as
with many other vaccine and specialty pharmaceutical product organizations.
Genetronics Biomedical Corporation
Genetronics Biomedical Corporation is a leader in electroporation therapy with 216 patents issued, allowed, or
pending. The Company utilizes its proprietary electroporation technology for the targeted intracellular delivery of
therapeutic materials, concentrating on drugs, vaccines, and gene therapy. In oncology, Genetronics has initiate d
Phase III clinical trials for the treatment of recurrent head & neck cancer. In gene therapy, Genetronics has
several collaborations with major biotechnology and pharmaceutical companies for the delivery of therapeutic
genes or vaccines using electroporation. Genetronics' BTX Division, a leader in molecular delivery, features
electroporation and electro fusion technology for research laboratory markets worldwide.
Geneva Pharmaceuticals (Member of the Novartis Group)
Broomfield, Colorado
Geneva Pharmaceuticals is one of the leading generic pharmaceutical manufacturers and marketers in the United
States. Recent acquisitions of Invamed (now called Geneva Pharmaceuticals Technology Co rporation, or GPTC)
and the marketing rights to Apothecon’s anti -infective and generic product lines have strengthened our position as
a market leader.
GenoMed
St. Louis, Missouri
GenoMed is a Next Generation Disease Management (tm) company that uses medical genomics to improve patient
outcomes. GenoMed is working to translate knowledge of medical genomics (the study of which genes cause
disease) into clinical practice: developing better drugs, usin g existing drugs for new indications, and identifying
diseases before symptoms arise. By studying disease genes, we hope to make medicine less invasive and more
proactive.
Genta
Two Connell Drive
Berkeley Heights, New Jersey 07922
Genta is a biopharmaceutical company that identifies, develops, and commercializes drugs for the treatment of
patients with cancer. We market drugs to a physician-centered healthcare system. Employees and shareholders
are rewarded by a corporate culture that values excellence in performance, innovation, quality, leadership and
absolute integrity. Genta"s rich pipeline is anchored by 4 key components: ;Antisense Technology; Androgenics
Products; Gallium Products; and Decoy Aptamers. The products from each of these platforms address significant
unmet medical needs, in markets that individually exceed $1 billion dollars annually. The Company"s lead
antisense compound, GenasenseTM, is currently in late-stage clinical trials for treatment of melanoma, multiple
myeloma, chronic lymphocytic leukemia and non-small cell lung cancer.
GenVec, Inc.
Gaithersburg, Maryland
GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to
the site of disease. GenVec has an exciting product portfolio, which includes TNFerade™ for the treatment of
cancer and BIOBYPASS® angiogen for the treatment of cardiovascular disease.
Genzyme Biosurgery
Genzyme Biosurgery (Nasdaq: GZBX) develops and commercializes implantable biotechnology products. It is
focused on three medical areas - orthopaedic disease and injury, serious heart disease, and improving the
outcomes of surgery. Within these areas, our portfolio includes a range of marketed biotherapeutics, biomaterials
and medical devices, with many more in the pipeline.
Genzyme General
Genzyme General, one of the three divisions of Genzyme Corporation, develops and commercializes innovative
solutions for major unmet medical needs of patients with gene tic and serious debilitating diseases. Genzyme
General is composed of five operating units: Genzyme Therapeutics, Genzyme Genetics, Genzyme Diagnostics and
Genzyme Pharmaceuticals.
Genzyme Molecular Oncology
Genzyme Molecular Oncology (Nasdaq: GZMO) is positioned where the power and promise of genomics and
biotechnology meet. It is utilizing its powerful proprietary functional genomics and antigen discovery technology
platforms to develop novel cancer products and to create a deep and promising product pipeline focused on cancer
vaccines and angiogenesis inhibitors. It is shaping these new therapies through the integration of its genomics,
gene and cell therapy, small-molecule drug discovery, and protein therapeutic capabilities.
Gilead Sciences, Inc.
Foster City, California
At Gilead, we are dedicated to advancing the care of patients suffering from life -threatening diseases worldwide.
Our research and development programs focus on nucleotides, liposomes, durable HIV inhibitors and other small
molecules. To date, Gilead's portfolio includes six marketed products and several clinical and preclinical products
in development.
Glades Pharmaceuticals, LLC
Suwanee, Georgia
Glades Pharmaceuticals is the generic division of Stiefel Laboratories, a company focusing specifically on products
for the skin since its inception in 1847. Being part of the world’s leading dermatology company has helped Glades
grow quickly since we launched our first product in 1991. Glades is now the leading dermatology -only generic
company with a variety of topical steroids, acne drugs, ant ibiotics, skin bleaches, and OTC’s.
GlaxoSmithKline
Brentford, Middlesex
GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of
skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare
environment. GSK's mission is to improve the quality of human life by enabling people to do more, feel better and
live longer. Headquartered in the UK and with ope rations based in the US, the new company is one of the industry
leaders, with an estimated seven per cent of the world's pharmaceutical market. GSK also has leadership in four
major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastrointestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of
oncology products.
Gliatech Inc.
Cleveland, Ohio
Gliatech Inc. is engaged in the discovery and development of biosurgery and pharmaceutical products. The
biosurgery products include ADCON(R) Gel (ADCON(R)-L & T/N) and ADCON(R) Solution, which are biopolymer
medical devices designed to inhibit scarring and adhesions following surgery. Gliatech's pharmaceutical product
candidates include proprietary monoclonal antibodies designed to inhibit inflammation.
Global Pharmaceuticals
Philadelphia, Pennsylvania
Global Pharmaceuticals is the generics marketing division of IMPAX Laboratories, Inc., a technology-based
specialty pharmaceutical company applying its formulation expertise and drug -delivery technology to the
development of controlled-release and niche products. Global’s multi -source product line consists of a growing
range of solid oral prescription pharmaceuticals, distributed primarily through drug wholesalers, distributors,
warehousing chains, and managed healthcare organizations.
GlycoGenesys, Inc.
Boston, Massachusetts
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology.
Our product development strategy focuses on therapeutic applications where there is an unmet medical need for
life threatening or debilitating diseases. The company's lead drug candidate, GCS -100, formerly known as GBC590, is a potential treatment for multiple forms of cancer.
Guilford Pharmaceuticals Inc.
Baltimore, Maryland
Guilford Pharmaceuticals Inc. was founded in July 1993 by Scios Nova Inc., Dr. Solomon H. Snyder and Dr. Craig
R. Smith to discover and develop novel pharmaceutical and biopolymer-based products that are intended to offer
new and better treatments for serious medical conditions like Parkinson's disease, Alzh eimer's disease, cancer and
diabetic peripheral neuropathy. To focus its efforts, the company has developed two innovative technology
platforms that have already spawned one commercial product and more than half a dozen novel product
candidates.
Gynétics Inc.
Gynétics' first major product was the PREVEN™ Emergency Contraceptive Kit, which was introduced in September,
1998. The original package has been supplemented with the addition of the PREVEN™ Emergency Contraceptive
Pills package in May 2000. Gynétics also markets the GynoSampler® Endometrial Curette, a diagnostic
endometrial tool that plays an increasingly important role within the in -office diagnostic environment. Endometrial
sampling should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring
abnormal uterine bleeding and as surveillance of all women taking estrogen as part of hormone replacement
therapy.
Hawthorne Pharmaceuticals, Inc.
Madison, Mississippi
Hawthorne Pharmaceuticals began in 1998 with two products and our sales professionals. Today, Hawthorne has
28 uniquely formulated products on the market with several more slatedfor introduction this year. Hawthorne
currently has over 100 sales professionals marketing products throughout the Southeastern United States.
Hawthorne Pharmaceuticals' corporate headquarters are located in Madison, MS.
Hoffmann-La Roche, Inc.
Nutley, New Jersey
Hoffmann-La Roche Inc. is the U.S. prescription drug unit of the Roche Group, a leading international health care
company with principal businesses in pharmaceuticals, diagnostics and vitamins. Roche provides more than 35
medications in the United States in major therapeutic areas including AIDS, cardiovascular diseases, central
nervous system disorders, dermatology, infectious diseases, oncology and transplantation.
Hospira, Inc.
Lake Forest, Illinois
Hospira is a specialty pharmaceutical and medication delivery company launched from the core global hospital
products business of Abbott Laboratories. Bringing proven leadership and a nearly 70 -year track record of
producing high-quality products, Hospira provides a breadth of technology solutions that help improve the safety
and effectiveness of patient care.
Hyseq Pharmaceuticals, Inc.
Sunnyvale, California
Hyseq Pharmaceuticals, Inc. is engaged in research and development of novel biopharmaceutical products from its
collection of proprietary genes discovered using its high-throughput screening-by-hybridization platform. This
platform provided a significant advantage in discovering novel, rarely -expressed genes, and assembly of one of
the most important proprietary databases of full-length human gene sequences. Hyseq intends to further elucidate
the physiological roles of its proprietary novel genes. Hyseq's database includes genes which encode a number of
therapeutically important classes of molecules including chemokines, growth factors, stem cell factors,
interferons, integrins, proteases, hormones, receptors, and other potential protein therapeutics or drug targets.
ICOS
Bothell, Washington
ICOS has spent more than a decade building a world-class research and development organization. Now, with
Cialis® available worldwide and several candidates in the pipeline, ICOS is poised to establish a powerful
commercial presence. The world's healthcare needs are more pressing than ever. Not only has the global
population expanded by more than 800 million people in the last decade, but the median age continues to grow
older as well. At ICOS, our mission is to target serious unmet medical needs -- and to address those needs with
novel, effective products that can improve the quality of life for millions of people.
IGEN International Inc
16020 Industrial Drive
IGEN develops and markets biological detection systems based on its proprietary ORIGEN technology, which
provides a unique combination of sensitivity, reliability, speed and flexibility. ORIGEN -based systems are used in a
wide variety of applications, including clinical diagnostics, pharmaceutical research and development, life science
research, biodefense testing and testing for food safety and quality control. These systems are marketed globally
by IGEN and its licensees and/or distributors. Merger with Roche completed 2/13 /2004.
igeneon
Vienna, Austria
igeneon is a biopharmaceutical company which focuses on cancer immunotherapies designed to prevent or delay
the formation of metastases in cancer of epithelial origin. It has built up a well balanced portfolio of cancer
immunotherapies. The three key products, which are broadly applicable, are undergoing clinical trials up to Phase
II/III. A number of innovative follow-up projects are also in the pipeline. igeneon is privately financed. Investors
include 3i, Novartis Venture Fund and Deutsche Venture Capital.
ImClone Systems Incorporated
New York, New York
ImClone Systems Incorporated is committed to advancing oncolog y care by developing a portfolio of targeted
biologic treatments, designed to address the medical needs of patients with a variety of cancers. The Company's
three programs include growth factor blockers, angiogenesis inhibitors and cancer vaccines. ImClone Systems'
strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the
research stage to the market. ImClone Systems' headquarters and research operations are located in New York
City, with additional administration and manufacturing facilities in Somerville, New Jersey.
ImmunoGen, Inc.
ImmunoGen, Inc. (Nasdaq: IMGN) develops innovative biopharmaceuticals for the treatment of ca ncer. The
Company's proprietary TAP technology combines extremely potent, cell -killing agents with monoclonal antibodies
that recognize and bind specifically to tumor cells. This targeted delivery technology increases the potency of
these cancer-specific antibodies, which allows the drugs to kill cancer cells with minimal harm to healthy tissue.
ImmunoGen’s TAP technology is designed to address the two fundamental limitations associated with traditional
chemotherapeutics: efficacy and tolerability.
IMPAX Laboratories, Inc.
Hayward, California
IMPAX Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation
expertise and drug delivery technology to the development of controlled-release and specialty generics in addition
to the development of branded products. IMPAX markets its generic products through its Global Pharmaceuticals
division and intends to market its branded products through the IMPAX Pharmaceuticals d ivision.
Incara Pharmaceuticals Corporation
4401 Research Commons, Ste 200
Research Triangle Park, North Carolina 27709
Incara Pharmaceuticals Corporation is focused on a new class of disease -modifying small molecules, the catalytic
antioxidants. Oxygen derived free radicals are a common step in neuronal death resulting from a variety of
causes. Incara's catalytic antioxidants have been shown to reduce damage to tissue in animal studies of
neurologic disorders such as amyotrophic lateral sclerosis (Lou Gehrig's disease) and stroke and in other non neurological indications such as cancer radiation therapy, chronic bronchitis and asthma.
Incyte Corporation
Wilmington, Delaware
Incyte is a Wilmington, Delaware-based drug discovery and development company with a growing pipeline of
novel small molecule drugs to treat HIV, inflammation, cancer and diabetes. The company's most advanced
product candidate, Reverset, is an oral, once-a-day therapy in Phase II clinical trials to treat patients with HIV
infections. Currently, Incyte has four drug discovery programs underway, an extensive intellectual property
portfolio and a proteomic information business based in Beverly, Massachusetts.
Indevus Pharmaceuticals, Inc.
We acquire, develop and commercialize products for multiple therapeutic areas, with a primary commitment
to urology, gynecology and men's health. Our robust clinical-stage pipeline has the potential to improve the
quality of life for millions of patients. We are focused on individual compounds, rather than on earlier stage,
relatively unproven drug discovery technologies. We continually seek product candidates for which we can define
clear clinical trial pathways and sound commercialization strategies. Our pipeline is highly dynamic, fueled by our
ability to identify and acquire promising new compounds and driven by our core competencies in clinical
development and regulatory review activities.
Innapharma, Inc.
Park Ridge, New Jersey
Innapharma, Inc. is engaged in the development of a series of "small chain" peptide -based products to treat
central nervous system disorders, with the Company's leading product being an antidepressant. Innapharma also
has a series of new tetracycline molecules in early development. These molecules may have activity against
certain cancers and rheumatoid arthritis, in addition to antibiotic activity. Initial testing has already provided
encouraging results in pre-clinical models.
Innovex
Parsippany, New Jersey
Integrity Pharmaceutical Corporation
Fishers, Indiana
Integrity Pharmaceutical's prescription products treat lower urinary tract pain and spasms; and provide women in
childbearing years optimal prenatal nutrition. Our generic drugs are valuable for patients and health care
providers because they represent high quality, low cost alternatives to many of today's commonly prescribed
medications.
InterMune, Inc.
Brisbane, California
InterMune is a commercially driven biopharmaceutical company focused on the marketing, development and
applied research of life-saving therapies for pulmonary disease, infectious disease and cancer. We market three
products: Actimmune® (Interferon gamma-1b), Infergen® (Interferon alfacon-1), and Amphotec® (Amphotericin
B Cholesteryl Sulfate Complex for Injection), and have a late -stage development pipeline including 15 active
clinical trials. Our lead clinical programs are focused on developing Actimmune for idiopathic pulmonary fibrosis,
ovarian cancer and liver fibrosis; developing oritavancin as a novel antibiotic for the treatment of serious Gram positive infections and developing a pegylated form of Infergen (PEG-Infergen) for chronic hepatitis C infections.
Introgen Therapeutics, Inc.
Austin, Texas
Introgen Therapeutics is a leader in the development and production of gene -based drugs for the treatment of
cancer and other diseases.
Inverness Medical Innovations
Inverness Medical Innovations manufactures and sells products for the women’s health and nutritional product
markets and is engaged in the business of developing, acquiring, manufacturing, and marketing advanced medical
device technologies. The Company’s women’s health and nutritional products are distributed to consumers through
established retail distribution networks such as Wal-Mart, Walgreens and CVS.
Invitrogen Corporation
Carlsbad, California
Invitrogen Corporation develops, manufactures and markets research t ools in kit form for biotechnology
researchers and companies worldwide. Our goal is to assist life scientists in accomplishing biological procedures
faster, more reliably and in a more cost effective manner. We offer thousands of products and services that
simplify and improve gene cloning, gene expression, and gene analysis techniques for corporate, academic and
government entities.
Ista Pharmaceuticals
ISTA Pharmaceuticals, Inc. engages in the discovery, development, and marketing of ophthalmic products for serious
diseases and conditions of the eye in the United States. The company’s products that are available for sale include Xibrom
for ocular inflammation and pain following cataract surgery, Istalol for the treatment of glaucoma, and Vitrase for use as a
spreading agent. Its products in the pipeline include Ecabet sodium, which is in Phase IIb clinical study for dry eye
syndrome; Tobramycin and Prednisolone Acetate combination product, which has completed Phase III clinical trials for
steroid-responsive inflammatory ocular conditions; Caprogel for hyphema, which is in the reformulations stage; and Strong
Steroid product for ocular inflammation and allergy, which is in the reformulation stage. The company sells its products to
drug wholesalers, retailers, and distributors, including chain drug stores, hospitals, clinics, government agencies, and
managed healthcare providers, such as health maintenance organizations and other institutions. ISTA Pharmaceuticals has
product licensing Collaborations with Allergan, Inc. and Otsuka Pharmaceutical Co., Ltd. The company was founded in 1992
as Advanced Corneal Systems, Inc. and changed its name to ISTA Pharmaceuticals, Inc. in 2000. ISTA Pharmaceuticals is
headquartered in Irvine, California.
IVAX Pharmaceuticals, Inc.
Miami, Florida
IVAX Pharmaceuticals, Inc develops, manufactures, and markets brand equivalent (generic) pharmaceutical
products, which are sold to wholesalers, retail drug chains, retail pharmacies, hospital groups, nursing home
providers, and government agencies in the United States. IVAX Pharmaceuticals is a subsidiary of Miami -based
IVAX Corporation, which is engaged in the research, development, manufacture, and marketing of branded and
brand equivalent pharmaceuticals worldwide. IVAX Pharmaceuticals is one of the premier brand equivalent drug
companies in the U.S., with an estimated 6% of the domestic market. IVAX Pharmaceutic als offers a balanced
product portfolio featuring specialty generics and a broad range of other brand equivalent products that meet the
needs of its customers. Under the "IVAX Pharmaceuticals" and "Goldline" trade names, IVAX Pharmaceuticals
manufactures and markets approximately 50 brand equivalent prescription drugs in capsule or tablet forms in an
aggregate of approximately 120 dosage strengths.
Janssen Pharmaceutica Products, L.P.
Titusville, New Jersey
Janssen Pharmaceutica Products, L.P., is a company driven by a dedication to product innovation, customer focus
and employee/organizational excellence. In the United States, medications now available in pharmacies include
drugs for the treatment of psychotic disorders, such as schizophrenia; mild to moderate Alzheimer's disease;
chronic pain; fungal infections; erosive gastroesophageal reflux disease (GERD); and duodenal ulcers. Janssen is
proud to be a member of the Johnson & Johnson family of compa nies.
Jazz Pharmaceuticals, Inc.
Palo Alto, California
We are a pharmaceutical company focusing on improving the lives of patients through the development and
commercialization of neurological and psychiatric products. We are committed to working closely with patients,
patient advocacy groups and healthcare professionals. At Jazz Pharmaceuticals, we are creating innovative
therapeutics by improving and expanding the uses of known compounds, and aggressive ly adding to our
pharmaceutical product portfolio through licensing, acquisitions and collaborations.
Johnson & Johnson
New Brunswick, New Jersey
Johnson & Johnson, with approximately 104,500 employees, is the world's most comprehensive and broadly -based
manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical
and medical devices and diagnostics markets. Johnson & Johnson has more than 197 operating companies in 54
countries around the world, selling products in more than 175 countries.
King Pharmaceuticals, Inc.
Bristol, Tennessee
King Pharmaceuticals is a vertically integrated pharmaceutical company that manufactures, markets, and sells
primarily branded prescription pharmaceutical products. King, an S&P 500 Index company, seeks to capitalize on
opportunities in the pharmaceutical industry created by cost containment initiatives and consolidation among large
global pharmaceutical companies. King's strategy is to acquire branded pharmaceutical products and to increase
their sales by focused promotion and marketing and through product li fe cycle management.
Kos Pharmaceuticals, Inc.
Cranbury, New Jersey
Kos Pharmaceuticals, Inc. – named after the Greek island where Hippocrates founded the science of medicine – is
a fully integrated specialty pharmaceutical company engaged in the development of proprietary prescription
pharmaceutical products, principally for treatment of cardiovascular, respiratory and metabolic diseases. The
Company’s principal product development strategy is to reformulate existing pharmaceutical products with large
market potential to improve safety, effectiveness and patient compliance.
Ligand Pharmaceuticals
Ligand is an emerging specialty pharmaceutical company that discovers, develops and markets innovative small
molecule drugs to address critical, unmet medical needs.
LigoCyte Pharmaceuticals, Inc.
920 Technology Boulevard, Suite C
Bozeman, Montana 59718
LigoCyte, established in 1998, focuses on cell -surface receptors that govern the way the human immune system
recognizes and responds to inflammatory events and infectious organisms. The company's immunomo dulatory
drug discovery and development activities support its pipeline of therapeutic candidates. LigoCyte has developed
the ProteoFlow® high content assay technology for the evaluation of inhibitors in human cells under physiologic
flow conditions. This powerful technology provides the company with a highly effective tool for predicting drug
behavior in animals and humans, streamlining the drug development process and reducing risk associated with
dosing efficacy.
Mallinckrodt, Inc.
Hazelwood, Missouri
Tyco Healthcare/Mallinckrodt, based in St. Louis, Missouri, manufactures and markets medical products. Our
mission is to improve healthcare for patients worldwide by providing superior products th at sustain breathing,
diagnose disease and relieve pain. We are committed to producing products that bring better healthcare to
patients, more value to medical professionals, greater opportunity to employees, and increased earnings to
reward Tyco shareholders.
Maxim Pharmaceuticals
Maxim Pharmaceuticals is a global bio-pharmaceutical company with a diverse pipeline of therapeutic candidates
for life-threatening cancers, hepatitis and other liver diseases.
MCR American Pharmaceuticals
Brooksville, Florida
MCR American Pharmaceuticals, Inc. was established in 1991. Our product line consists of Allfen, Ambifed, Ambi,
Maxifed, Maxinate, Maxiphen, Maxi-Tuss, Pro-Fast, and Promacet. Our sales representatives are located
throughout the United States. We will continue to increase our sales force throughout the country and abroad.
MedImmune, Inc.
MedImmune, Inc. is a fully integrated biotechnology company founded in 1988. It is focused on developing and
marketing products that address medical needs in areas such as infectious disease, immune regulation, and
cancer. The company's capabilities span the entire spectrum of pharmaceutical development, including discovery
research, clinical development, data analysis, regulatory affairs, quality control, manufacturing, and sales and
marketing.
MGI Pharma
Bloomington, Minnesota
MGI PHARMA, INC. is an oncology and acute care focused biopharmaceutical company that acquires, researches,
develops and commercializes proprietary products that address the unmet needs of patients. MGI PHARMA has a
portfolio of proprietary pharmaceuticals, and intends to become a leader in oncology and acute care. MGI PHARMA
markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen™ (decitabine) for Injection and Gliadel®
(polifeprosan 20 with carmustine implant) Wafer in the United States. The Company directly markets its products
in the U.S. and collaborates with partners to reach international markets.
Memory Pharmaceuticals Corp.
100 Philips Parkway
Montvale, New Jersey 07645
Memory Pharmaceuticals, a biopharmaceutical company, is focused on developing innovative drugs for the
treatment of debilitating central nervous system (CNS) disorders such as Alzheimer’s Disease, depr ession,
schizophrenia, vascular dementia, Mild Cognitive Impairment, and memory impairments associated with aging.
The Company’s customized drug development infrastructure emphasizes rigorous target identification and
compound screening procedures, medicinal chemistry, neurobehavioral biology, and sophisticated IT systems.
Advanced capabilities and in-house expertise in drug discovery and development have allowed the Company to
generate a diverse pipeline of promising drug development programs.
Medicis Pharmaceutical Corporation
Scottsdale, Arizona
Medicis is the leading independent specialty pharmaceutical company in the United States focusing primarily on
the treatment of dermatological and podiatric conditions and aesthetics medicine. The Company is dedicated to
helping patients attain a healthy and youthful appearance and self -image. Medicis has leading branded
prescription products in a number of therapeutic categories, including acne, eczema, fungal infections, psoriasis,
rosacea, seborrheic dermatitis and skin and skin-structure infections. Additionally, the company markets the
leading dermal filler in the U.S., Restylane.
Merck & Company, Inc.
Whitehouse Station, New Jersey
Merck & Co., Inc. is a leading research-driven pharmaceutical products and services company. Merck discovers,
develops, manufactures and markets a broad range of innovative products to improve human and animal health.
The Merck-Medco Managed Care Division manages pharmacy benefits for more than 40 million Americans,
encouraging the appropriate use of medicines and providing disease management programs.
Medpointe Pharmaceuticals
Somerset, New Jersey
MedPointe is a specialty pharmaceutical company that develops, markets and sells branded prescription
therapeutics. Although the company was founded in 2001, it draws upon a long history. It entered the market with
the acquisition of Carter-Wallace, Inc., a long-established enterprise. MedPointe is headquartered in Somerset,
New Jersey, in the heart of the nation's pharmaceutical corridor.
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals currently markets two products, the cardiovascular drug INTEGRILIN® (eptifibatide)
Injection and the oncology drug VELCADE™ (bortezomib) for Injection. These are examples of the types of drugs
Millennium expects to develop in four key therapeutic areas: Cancer, Cardiovascular diseases, Inflammation and
Metabolic disorders.The company also has a significant number of investigational drugs at various stages of
clinical and preclinical development, as describe d in the R&D section of this website, and played a significant role
in bringing the oncology drug Campath® (alemtuzumab) Injection to market.
Metagenics
Metagenics is the ‘practitioner only’ products division of Health World Limited - the Australian and New Zealand
leader in research and development of specialised nutritional supplements for healthcare professionals.
Miravant Medical Technologies
336 Bollay Drive
Santa Barbara, California 93117
Miravant Medical Technologies specializes in pharmaceuticals and devices for photoselective medicine, developing
its proprietary PhotoPoint photodynamic therapy (PDT) for large potential marke ts in ophthalmology, dermatology,
cardiovascular disease and oncology. PhotoPoint PDT uses photoreactive (light -activated) drugs to selectively
target diseased cells and blood vessels.
Email: [email protected]
Molnlycke Health Care
Goteborg, Sweden
Mölnlycke Health Care is one of the world’s leading manufacturers of single -use surgical products – patient
drapes, instrument drapes and surgical gowns, caps and masks for operating staff. The group also has a strong
international standing in the professional wound care sector, with a wide range of products for the treatment of
surgical wounds, chronic wounds and burns. Total annual sales are at present SEK 4,500M and the company has
app. 4,000 employees. Of these, about 3,300 are involved in production at f actories in Belgium, Finland, Mexico,
Thailand and Czech Republic. Headquarters in Göteborg, Sweden is home to all group staff functions as well as
business area management, sales management and Global Supply, which includes, e.g procurement, logistics and
IT. The major shareholders in Mölnlycke Health Care are Nordic Capital and the Sixth National Pension Fund. Two
business areas: Operations are divided into two business areas – Surgical and Wound Care. Surgical business area
products are sold under the brand names Klinidrape® and BARRIER®. Wound Care business area products are
sold under the Tendra® brand. Sales and marketing: Sales and marketing of both business areas are the
responsibility of three joint organisations, one for the US, one for Europe and one for other markets. Twenty
subsidiaries and several branch sales offices and distributors are included in the organisation.
Mylan Laboratories Inc.
1500 Corporate Drive Suite 400
Canonsburg, Pennsylvania 15317
Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc.,
Mylan Technologies Inc., UDL Laboratories, Inc. and Bertek Pharmaceuticals Inc., that develop, manufacture and
market an extensive line of generic and proprietary prescription products. Mylan markets its branded
pharmaceuticals through Bertek Pharmaceuticals Inc. Bertek operates as a stand -alone proprietary pharmaceutical
company with independent clinical development, business development and sales and marketing efforts. Bertek is
a transitional pharmaceutical company that will enable Mylan to grow from a traditional generic company to a
proprietary based company. The Company's strategy is to optimize marketing and sales through a targeted
therapeutic focus on neurology, dermatology and cardiology, thereby enabling our field sales representatives to
concentrate on a narrow physician call base, as well as developing new products as trading stock for other Bertek
products. Bertek's vision is to be a growth oriented, highly profitable pharmaceutical company that efficiently
commercializes significant improvements to human healthcare.
NaPro BioTherapeutics, Inc.
4840 Pearl East Circle, #300W
Boulder, Colorado 80301
NaPro BioTherapeutics, Inc., is a life science company focused in two distinct therapeutic areas: the development
of proprietary anti-cancer agents and the development of genomic therapies for inherited disease, primarily
through the use of our novel "gene editing" technology.
Nektar Therapeutics
San Carlos, California
Nektar Therapeutics (NASDAQ:NKTR) provides a portfoli o of leading drug delivery solutions that enable the
development of high-value pharmaceutical products. Formed through the fusion of Inhale Therapeutic Systems,
Shearwater, and Bradford Particle Design, our company offers a suite of leading drug delivery t echnologies that
encompasses molecule engineering including advanced pegylation, particle engineering comprising both pulmonary
particle technology and supercritical fluid technology (SCF), and advanced drug delivery solutions for oral,
injectable, and pulmonary administration.
NeoGenesis Pharmaceuticals, Inc.
840 Memorial Drive
Camgridge, Massachusetts 02139
NeoGenesis Pharmaceuticals, Inc. is a drug discovery comp any focused on using its proprietary drug discovery
technologies to discover and develop a portfolio of small molecule -based drugs, both for itself and for its
collaboration partners. The company's universal, unbiased, affinity-based technologies, coupled with millions of
diverse medicinally relevant compounds, provide an unmatched efficiency in lead discovery and optimization.
NeoGenesis' core technology, the Automated Ligand Identification System (ALIS), is a rapid and universal affinity based system for identifying and optimizing novel drug leads. Coupled with the company's NeoMorph compound
library, consisting of more than 10 million diverse medicinally relevant small molecules, ALIS enables the
identification of novel and selective drug leads against validated and emerging new genomic targets.
NeoRx Corporation
300 Elliott Avenue West, Suite 500
Seattle, Washington 98119
NeoRx is a cancer therapeutics company developing products for targeted deliver y of anti-cancer agents, including
radiopharmaceuticals, to tumor sites.
Neurion Pharmaceuticals, Inc.
180 North Vinedo Avenue
Pasadena, California 91107
Neurion Pharmaceuticals, Inc. is a privately held, development-stage pharmaceutical company that is focused on
the discovery of novel drugs for central nervous system (CNS) diseases and other disorders associated with ion
channels. The Company uses its proprietary discovery platform technology t o understand the structural basis of
drug-ion channel interactions, and to design safer and more effective drugs by exploiting this knowledge.
Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a biopharmaceutical company focused on the discovery and development of novel
therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The
Company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the
molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic
interventions for anxiety, depression, multiple sclerosis, insomnia, brain can cer, obesity and diabetes.
NitroMed
NitroMed, Inc. of Lexington, Massachusetts is a research-based emerging pharmaceutical company and the maker
of BiDil, an orally administered medicine available in the United States for the treatment of heart failure in self identified black patients. In this population, BiDil is indicated as an adjunct to current standard therapies such as
ACE inhibitors and/or beta blockers. BiDil was approved in June 2005 by the U.S. Food and Drug Administration,
primarily on the basis of efficacy data from the Company's landmark A-HeFT (African American Heart Failure Trial)
clinical trial, and since July 2005, has been marketed by NitroMed through a nationw ide, dedicated contract sales
force. The Company is committed to the development of novel pharmaceuticals and safer, more effective versions
of existing drugs to treat underserved patient populations. NitroMed's development efforts are primarily directed
at expanding its cardiovascular franchise.
Novartis Pharmaceuticals
New York, New York
Novartis is a global company that touches your life in ways you might no t have imagined. Our employees make
products that range from life-saving drugs for organ transplantation to state -of-the-art contact lenses, from
affordable generic medicines to a famous name in baby food, from trusted over -the-counter brands against the
common cold to products that protect farm animals and your beloved pets from parasites and disease. What do
these business areas have in common? They are all powered by science and innovation. Novartis invests
approximately 4 billion Swiss francs every year in research and development. We are exploring new scientific
horizons and applying the latest technologies to lead future breakthroughs.
Novavax, Inc.
Novavax, Inc. is a specialty biopharmaceutical company engaged in the research, development and
commercialization of proprietary products focused on drug delivery and biological technologies.
Novo Nordisk
Plantation, Florida
Novo Nordisk is a focused healthcare company. With the broadest diabetes product portfolio in the industry,
including the most advanced products within the area of insulin delivery systems, Novo Nordisk is the worl d leader
in diabetes care. In addition, Novo Nordisk has a leading position in areas such as haemostasis management,
growth disorders and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical
products and services that make a significant difference to patients, the medical profession and society.
NPS Pharmaceuticals
Salt Lake City, Utah
NPS Pharmaceuticals is engaged in the discovery and development, and is preparing for the co mmercialization of
therapeutic small molecules and recombinant proteins. Current product candidates include treatments for bone
and mineral disorders (osteoporosis & hyperparathyroidism), gastrointestinal disorders (GI) and central nervous
system disorders (CNS). Our objective is to build a profitable company by using our scientific development and
marketing expertise, which will allow us and the patients who use our drugs, to reap the value of our efforts. We
are creating a diversified pipeline of products in all stages of development from discovery research, to preclinical
testing, to clinical trials.
Nymox
230 West Passaic Street
Maywood, New Jersey 07607
Nymox Pharmaceutical Corporation is a biopharmaceutical company based in Maywood, New Jersey and Saint
Laurent, Quebec. It has two subsidiaries, Nymox Corporation and Serex, Inc. Nymox specializes in the research
and development of therapeutics and diagnostics for the aging population with an emphasis on Alzheimer's
disease. Nymox was incorporated in 1989 and became a public company in 1995. Nymox was founded around a
group of distinguished career scientists with long established interests in brain diseases and Alzheimer’s disease in
particular. Nymox is the first company to have successfully developed an accurate peripheral test for this
devastating disorder, the AlzheimAlert™ test. Nymox’s strong scientific relationships have led to the development
every year of at least one major new project initiative. Nymox currently markets its AlzheimAlert™ test to
physicians in the U.S. and its NicAlert™ test for tobacco exposure both in the U.S. and Japan. Nymox has an
exciting pipeline of drugs in development and a proprietary antimicrobial treatment against dea dly E. coli
contamination. Nymox also has a line of other “Alert” products (such as OsteoAlert™ for osteoporosis) in
development, as well as a unique proprietary diagnostic platform technology. Email: [email protected].
OctaPharma
Centreville, Virginia
Octapharma, a Swiss-based company, is an independent, global plasma fractionation specialist. Its core business
is the development, production and sale of high quality plasma derivatives. From its foundation in 1983 the
company has grown to employ over 1482 people in 27 countries. Octapharma owns four modern, state -of-the-art
production facilities in Austria, France, Sweden and Mexico. Since 2005 Octapharma also opperates the
NSTOB plant in Springe Germany. Sales turnover in 2005 exceeded Euro 421 million .
Organon USA
Roseland, New Jersey
Organon is a renowned global pharmaceuticals company with a strong commitment to hu man health care. The
company develops and produces innovative prescription medicines for women's health, mental health,
cardiovascular disease, immunology, and anesthesiology. Organon products are sold in over 100 countries, more
than half of which have an Organon subsidiary. Organon was founded in 1923 and is a business unit of the Pharma
division of Akzo Nobel, NV. The Pharma division consists of three business units – Organon, Intervet and
Diosynth.
Odyssey Pharmaceuticals, Inc.
East Hanover, New Jersey
OddyssyPharmaceuticals, Inc., a premier fast growing specialty Pharmaceutical Company, is dedicated to serving
the healthcare needs of the community by providing physicians, pharmacists, and patie nts with an expanding line
of unique branded pharmaceutical products developed to help people with different medical needs to live
healthier, more productive lives.
Ortho-McNeil Pharmaceuticals
Raritan, New Jersey
Ortho-McNeil, a Johnson & Johnson company, is based in Raritan, NJ. The company markets pharmaceutical
products in several therapeutic categories including infectious diseases, central nervous system, wound healing,
urology and women's health.
OraPharma, Inc
Warminster, Pennsylvania
Founded in 1996 by David Scheer, OraPharma, Inc., is dedicated to the research, development, and marketing of
products for oral healthcare. OraPharma's lead product, ARESTIN® (minocycline HCl 1 mg) microspheres, which
received FDA approval on February 16 2001, is indicated as an adjunct to SRP procedures for reduction of pocket
depth in patients with adult periodontitis. Periodontitis affects more than 50 million people in the United States,
less than one-fifth of whom receive treatment.
OSI Pharmaceuticals
58 South Service Road Suite 110
Melville, New York 11747
OSI Pharmaceuticals is a leading biotechnology company focused on the discovery, development, and
commercialization of high-quality, next-generation oncology products that both extend and improve the quality-oflife for cancer patients worldwide. OSI has a balanced pipeline of oncology drug ca ndidates that includes both
next-generation cytotoxic agents and novel mechanism-based, gene-targeted therapeutics focused in the areas of
signal transduction and apoptosis. OSI has a commercial presence in the U.S. oncology market where it
exclusively markets Novantrone® (mitoxantrone concentrate for injection) for approved oncology indications and
Gelclair(TM) for the relief of pain associated with oral mucositis. Our most advanced drug candidate is Tarceva™
(erlotinib HCl), a small-molecule inhibitor of the epidermal growth factor receptor, or HER1/EGFR. We believe
HER1/EGFR inhibitors represent an exciting new class of relatively safe and well -tolerated anti-cancer agents that
may have utility in treating a wide range of cancer patients. Tarceva™ is an o ral once-a-day small molecule drug
designed to specifically block the activity of the HER1/EGFR protein and has demonstrated encouraging indications
of anti-cancer activity in single-agent, open label Phase II trials in non-small cell lung cancer, head and neck
cancer and ovarian cancer. Tarceva™ is being developed in an alliance with Genentech, Inc. and Roche and is
currently in Phase III clinical trials for non-small cell lung cancer and pancreatic cancer.
Ortho Biotech
Ortho Biotech Products, L.P. is a leading biopharmaceutical company that provides innovative products and
services designed to help enhance the lives of individuals with serious chronic illnesses. We market a prescription
medication for chemotherapy-related anemia in patients with most types of cancer, for kidney disease patients
with anemia who are not on dialysis, for anemia induced by AZT -containing regimens in HIV patients, and for
patients undergoing elective, non-cardiac, non-vascular surgery who are anemic. More than two million patients in
the United States alone have been treated with our products.
Oscient Pharmaceuticals
Oscient Pharmaceuticals Corporation is a biopharmaceutical company committed to the clinical development and
commercialization of novel therapeutics to address unmet medical needs. The Company is marketing FACTIVE®
(gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic
bronchitis and community-acquired pneumonia of mild to moderate severity. In addition to the oral tablet form,
Oscient Pharmaceuticals is developing an investigational FACTIVE intravenou s formulation for use in hospitalized
patients.
Perlegen Sciences, Inc.
Perlegen Sciences, Inc. is a private company that uses high -density, whole-wafer microarray technology in
combination with new approaches to sample preparation to scan entire human genomes. The company's first
objective is to read 50 different human genomes at a single base resolution, discovering and analyzing the
patterns of genetic variation between them. Then, using what it has learned about genome-wide haplotype
patterns by reading the first 50 genomes, Perlegen will scan the DNA of thousands of individuals with
pharmaceutical partners, in order to associate genetic haplotypes with disease and drug r esponse. The company
will also conduct downstream research aimed at elucidating the biology underlying those genotype -phenotype
associations in order to accelerate the discovery of new drugs and the modification of existing treatments.
Pfizer Inc
New York, New York
Pfizer Inc is a research-based, global pharmaceutical company. We discover and develop innovative, value -added
products that improve the quality of life of people around the worl d and help them enjoy longer, healthier, and
more productive lives. The company has three business segments: health care, animal health and consumer
health care. Our products are available in more than 150 countries.
Pan American Laboratories, LLC
Covington, Louisiana
For almost fifty years, Pamlab, L.L.C. has served the medical profession and their patients with novel, quality
pharmaceuticals. Pamlab's predecessor, Pan American Laboratories, Inc., had a focus on respiratory products,
including antihistamine/decongestant combinations, and various other cough/cold/allergy combination products.
Today, Pamlab has emerged as the U.S. leader in the development of therapies addressing homocysteine -related
diseases and conditions, as well as other diseases and conditions benefiting from novel folate therapy
Pharmacia Corporation
Pharmacia is a top-tier global pharmaceutical company. We have buil t a portfolio of outstanding products, led by
our key growth drivers: CELEBREX® (celecoxib capsules), CAMPTOSAR® (irinotecan hydrochloride injection),
XALATAN® (latanoprost ophthalmic solution), DETROL®LA (tolterodine tartrate extended release capsules), a nd
ZYVOX™ (linezolid injection, tablets, and for oral suspension). Acquisition by Pfizer, Inc. announced in April
2003.
Par Pharmaceutical Companies, Inc.
Spring Valley, New York
Par Pharmaceutical Companies, Inc. (Par) develops, manufactures, and markets generic drugs and innovative
branded pharmaceuticals for specialty markets. In July 2005, Par received approval for and introduced Megace®
ES, the company's first branded pharmaceutical product. We expect to launch our second brand some time in
2006. Our Generic Products Division is committed to providing high-quality pharmaceuticals that are affordable
and accessible to patients. Par ranks fifth in sales among all U.S. generic companies, a ccording to IMS Health. We
currently manufacture, market, or license more than 110 prescription drug products.
Pharmacyclics, Inc.
Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches
to cancer and atherosclerosis. The company's products are rationally designed, ring -shaped small molecules called
texaphyrins that disrupt the bioenergetic processes of diseased cells, such as cancer and atherosclerotic plaque.
When activated by various forms of energy, including X-ray and light, these texaphyrins can help to reduce or
eliminate the diseased tissue.
PDI, Inc.
Saddle River, New Jersey
PDI, Inc. (NASDAQ: PDII) is a diversified sales and marketing services provider to the biopharmaceutical industry
offering a comprehensive set of outsourced solutions for established and emerging pharmaceutical companies. PDI
is dedicated to maximizing the return on investment for its clients by providing strategic flexibility; sales,
marketing, and commercialization expertise; and a philosophy of performance.
PharmaNetics, Inc.
Raleigh, North Carolina
PharmaNetics, Inc., a leading biotech company, conceived the term "theranostics," defining an emerging new field
of medicine that enables physicians to monitor the effect of antithrombotic agents in patients being treated for
angina, myocardial infarction (heart attack), stroke, and pulmonary and arterial emboli. The Company develops,
manufactures and markets rapid turnaround diagnostics to assess blood clot formation and dissolution.
PharmaNetics develops tests based on its proprietary, dry chemistry Thrombolytic Assessment System for its
principal target market of managing powerful new drug compounds, some of which may have narrow therapeutic
ranges, as well as for monitoring routine anticoagulants.
Plexxikon
91 Bolivar Drive
Berkeley, California 94710
Plexxikon is a leader in the discovery and development of novel small molecule pharmaceuticals to treat human
disease. Since operations commenced June 2001, Plexxikon has applied i ts proprietary platform technology to
identify and build a portfolio of product opportunities for therapeutic indications in metabolic disorders,
cardiovascular disease, inflammation and oncology. Current Plexxikon programs address disease targets that are
already validated in humans, have clear clinical development paths for significant unmet markets, and
demonstrate Plexxikon's capability to address side effects and/or enhance the therapeutic profile of current drug
treatments. Plexxikon's discovery process utilizes a number of technologies, including Plexxikon's Scaffold-Based
Drug Discovery™ platform. This discovery platform involves structural screening and analysis as one key
component providing a significant competitive advantage to other drug discove ry approaches. Structural screening
is applied at the earliest point in lead finding to address current challenges in pharmaceutical drug discovery
today – by enabling the mining of novel chemical space, applying a unique quality filter, and by providing a
roadmap for lead discovery and development chemistry.
Pressure BioSciences, Inc.
375 West Street
West Bridgewater, Massachusetts 02379
Following the sale of substantially all the assets and selected liabilities of its BBI Diagnostics and BBI Biotech
Divisions to SeraCare Life Sciences, Inc. on September 14, 2004, Boston Biomedica changed its name to Pressure
BioSciences, Inc (PBI). PBI is a publicly traded, early-stage company focused on the development of a novel
technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient
and ultra-high levels (35,000 psi and greater) to control bio- molecular interactions. PBI currently holds 13 US
and foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as
genomic and proteomic sample preparation, pathogen inactivation, control of enzymes, immunodiagnostics, and
protein purification. PBI owns a 30% passive investment in Source Scientific, LLC, an instrumentation company
that develops and manufactures PBI's PCT equipment, as well as a 4.45% passive investment in Panacos
Pharmaceuticals, an antiviral drug discovery and development company.
Proctor & Gamble Pharmaceuticals, Inc.
Procter & Gamble Pharmaceuticals is a division within Procter & Gamble Health Care. P&G Health Care includes
over-the-counter medications, oral care products and other health care products. P&G Pharmaceuticals is a
research-based global organization dedicated to creating and delivering solutions that improve the health and
well-being of people around the world. We are building a highly innovative organization with world class talent in
discovery, development and marketing in a distinctive environment with its own spirited culture. Our people are
driven by a desire to understand and address the needs of patients, partners, providers, and customers around
the world in everything we do – from early discovery research to patient support groups for our marketed
products.
Proneuron Biotechnologies, Inc.
Ness-Ziona, Israel
Proneuron is a biopharmaceutical company developing cell therapies and other treatment modalities for
neurological, ophthalmological and immune-related disorders such as spinal cord injury, multiple sclerosis,
glaucoma, Parkinson's and Alzheimer's diseases. Proneuron's unique technologies, developed at the Weizmann
Institute, are based on the modulation of natural mechanisms within the body to address currently incurable
disorders.
ProEthic Pharmaceuticals
Montgomery, Alabama
ProEthic Pharmaceuticals, Inc., a Montgomery, Alabama company was created in May 2001 in Alabama for the
purpose of acquiring, licensing, marketing, developing and distributing pharmaceutical products. It is a specialty
pharmaceutical company which promotes its own branded prescription products to physicians across many
specialties. It also has an active drug development program with two products currently in Phase III clinical trials.
Purdue Pharma L.P.
Stamford, Connecticut
Purdue is part of an international group of associated independent companies engaged in the research,
development, production, sales, and licensing of both prescription and over -the-counter medicines and hospital
products. The company seeks to continually develop and sell new, high-quality, innovative pharmaceutical
preparations, which together with clinical data and medical education create new value for patients and the health
care system. Our sales, marketing, and medical education professionals provide the healthcare community with
comprehensive educational materials and programs relating to Purdue products. These products include
OxyContin® (oxycodone HCl controlled-release) Tablets, MS Contin® (morphine sulfate controlled-release)
Tablets, Uniphyl® (theophylline, anhydrous) Tablets, Chirocaine® (levobupivacaine injection), and the popular
over-the-counter Senokot® Laxatives, Betadine® Microbicides, and Betadine® Brand Antibiotics.
Pometheus Laboratories
Prometheus integrates therapeutics and diagnostics to individualize medicine. Prometheus Laboratories Inc. is a
specialty pharmaceutical company committed to developing new ways to help physicians individualize patient
care. Prometheus is built upon a foundation of successful relationships with physician specialists. Prometheus
markets and delivers proprietary, high-value diagnostic testing services which complement the company's
pharmaceutical products. Prometheus diagnostics include non-invasive testing to help expedite difficult diagnoses.
Prometheus products provide pharmacogenetic evaluations, which assist in therapy management. Prometheus
services also enable metabolism-based dosing to further individualize treatment.
Publicis Selling Solutions
Lawrenceville, New Jersey
Publicis Selling Solutions offers a complete range of proven, results -based selling solutions. We're experts at
working with you to customize the right strategy, define the performance metrics, and implement the tactics
necessary to drive your product sales. Our extensive background in sales management enables us to offer greater
value than other CSOs. We excel at building products through selling, gaining market share, and maximizing a
brand's life cycle. Our focus on performance versus “just activity” clearly distinguishes Publicis Selling Solutions
from the typical CSO. We provide the strategic insights that translate into solutions that will exceed your
expectations. From launching and managing blockbuster products to breaking new ground in cutting -edge
specialty markets, we've done it all. We can do the same for you. As part of the Publicis Healthcare Group, w e
have access to the number one healthcare communications company in the world.1 We offer a complete range of
value-added, non-CSO services to ensure that every marketing option is always available to distinguish your
product.
Ranbaxy Laboratories Limited
India's largest pharmaceutical company, Ranbaxy Laboratories Limited, is today well positioned in its quest to
become a research-based international pharmaceutical company. Ranbaxy is amongst the top p harmaceutical
companies in the world. It has been rated the 11th largest Generic Company Worldwide. The Company exports its
products to over 70 countries with ground operations in 25 and manufacturing facilities in 7 countries.
Ribapharm Inc.
Costa Mesa, California
Ribapharm is a biopharmaceutical company that seeks to discover, develop, acquire and commercialize innovative
products for the treatment of significant unmet medical needs, principally in t he antiviral and anticancer areas.
NOTE: Acquisition by ICN Pharmaceuticals announced 25 August 2003.
Rubicon Genomics, Inc.
Ann Arbor, Michigan
Rubicon Genomics’ novel OmniPlexTM technology reformats naturally-occurring chromosomes into new molecules
called Plexisomes™. Plexisomes represent an entire genome as DNA units of controlled length that can be
amplified in a highly multiplexed fashion. The unique structure of Plexisomes allows large r egions of a genome to
be analyzed up to hundreds of times more efficiently than cloning or PCR. Hundreds of thousands of DNA bases
can be amplified simultaneously from single loci or multiple loci.
Reliant Pharmaceuticals, Inc.
Liberty Corner, New Jersey
Reliant is a pharmaceutical company with integrated sales, marketing and development expertise that markets a
portfolio of branded cardiovascular pharmaceutical products. The Company focuses on marketi ng promotionally
sensitive pharmaceutical products to the high prescribing primary care, cardiovascular and specialist physician
markets in the United States. The Company further enhances the value of its product portfolio by implementing
strategies to extend the life cycle of the products that it markets. In addition, Reliant acquires rights to branded
pharmaceutical products that typically have regulatory exclusivity or patent protection. Reliant also acquires
rights to and develops product candidates in mid- to late-stage clinical development. This approach seeks to
minimize many of the risks associated with the drug discovery process.
Roche (F. Hoffman-La Roche Ltd.)
Roche is a leading healthcare company with a uniquely broad spectrum of innovative solutions. For more than 100
years, we have been active in the discovery, development, manufacture and marketing of novel healthcare
solutions. Our products and services address prevention, diagnosis and treatment of diseases, thus enhancing
well-being and quality of life. Our focus is not just the diagnosis and treatment of manifest disease. The
integrated healthcare approach is increasingly offering ways of identifying and targeting diseases early, w hen
their damaging effects can still be prevented.
Romark Laboratories, L.C.
Tampa, Florida
Headquartered in Tampa, Florida, Romark has a global footprint and perspective. The company conducts drug
discovery research in the United Kingdom and Switzerland, has clinical trials underway on virtually every
continent, and markets its products internationally. Romark has a rich history in discovery and development of
new treatments for infectious and gastrointestinal diseases. Among the company's significant accomplishments is
the discovery and development of the anti-infective nitazoxanide. The drug, for which Romark has obtained more
than 100 patents worldwide, is marketed in the United States under the trade name Alinia.
Salix Pharmaceuticals, Inc.
Raleigh, North Carolina
Salix Pharmaceuticals is dedicated to being the leading specialty pharmaceutical company providing products
to gastroenterologists and their patients. Our "search and development" efforts are designed to identify and
acquire late-stage and/or marketed proprietary pharmaceutical products that have an existing base of safety
and efficacy data for the treatment of gastrointestinal disease. Thi s focus on late-stage products serves to
reduce the risk, time and expense Salix invests in products compared to the investment typically associated
with the research and early development phases of pharmaceutical products.Salix has a direct sales force to
promote its products to the fastest- adopting, highest-prescribing physicians in the U.S. responsible for
treating gastrointestinal disease. We believe that our specialty sales force – and the high level of service we
are able to provide - allows us to capitalize on the opportunity to build a franchise with the gastroenterology
community. We also believe that our specialty sales force allows us to attain the higher profit margins and
benefits of direct control over distribution that comes with selling prod ucts directly.
SangStat Medical Corporation
6300 Dumbarton Circle
Fremont, California 94555
SangStat Medical Corporation is a global biotechnology company focused on immunology and working to
discover, develop and market high value therapeutic products in the autoimmune, hematology/oncology and
immunosuppression areas. NOTE: Acquisition by Genzyme Corporation announced 8/04/2003.
sanofi-aventis Group
New York, New York
The sanofi-aventis Group is the world’s 3rd largest pharmaceutical company, ranking number 1 in Europe.
Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major
therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal
medicine, and vaccines. The sanofi-aventis Group is listed in Paris and New York.
Sankyo (Daiichi-Sankyo)
Tokyo, Japan
DAIICHI SANKYO COMPANY, LIMITED has taken the first steps toward challenging the world market by
becoming a Japan-Based Global Pharma Innovator on September 28, 2005. We continue to provide innovative
pharmaceuticals to meet the medical needs of people all over the globe.
Schering-Plough Corporation
Kenilworth, New Jersey
As a worldwide, research-based pharmaceutical company, we are engaged in the discovery, development,
manufacturing and marketing of new therapies and treatment programs that can improve people's health and
extend their lives. Our primary business involves prescription products in core product categories, including:
Allergy and respiratory, Anti-infective and anticancer, Cardiovasculars, Dermatologicals, Central nervous
system and other disorders.
Santarus, Inc.
We are a specialty pharmaceutical company focuse d on acquiring, developing and commercializing proprietary
products that treat gastrointestinal diseases and disorders and enhance the quality of life for patients. Our
current products are immediate-release formulations of omeprazole, a widely prescribed proton pump
inhibitor, or PPI. PPIs are the most frequently prescribed drugs for the treatment of many upper
gastrointestinal, or GI, diseases and disorders. We currently market ZEGERID® (omeprazole/sodium
bicarbonate) Capsules and ZEGERID (omeprazole/sodium bicarbonate) Powder for Oral Suspension. These
products are the first and only immediate-release oral PPIs approved by the U.S. Food and Drug
Administration, or FDA, for commercial sale in the U.S.
Scios Inc.
Scios Inc. is a biopharmaceutical company developing novel drugs for the potential treatment of cardiovascular
and inflammatory diseases. We are distinguished by our disease -based technology platform which integrates
expertise in protein biology with computational and medicinal chemistry to identify novel targets and rationally
design small-molecule compounds. Scios has received approval from the U.S. Food and Drug Administration to
market Natrecor (nesiritide) for the treatment of patients with acutely decompensated congestive heart failure
who have shortness of breath (dyspnea) at rest or with minimal activity. Natrecor is a new drug class, human
B-type Natriuretic Peptides, made available as a therapeutic in the United States.
Savient Pharmaceuticals, Inc.
East Brunswick, New Jersey
There has never been a more challenging and exciting time at Savient. In 2005, we continued to refine our
focus as a specialty pharmaceutical company and advanced the development of our clinical pipeline by
completing critical clinical programs for both Prosaptide and Puricase (PEG -uricase). Based upon a scheduled
interim analysis of the Prosaptide data, we decided to halt this Phase 2 clinical trial early in the year.
Although the outcome was not what we were hoping for, this planned analysis allowed us to save significant
time and money by stopping the trial at that particular stage.
Serologicals Corporation
Norcross, Georgia
Serologicals' antibody-based products are used as the active ingredients in therapeutic products for the
treatment and management of diseases, such as Rh incompatibility in newborns, rabies and hepatitis and in
diagnostic products such as blood typing reagents and diagnostic test kits. The Company also provides a
variety of proteins used in the manufacturing of diagnostic reagents and genetically engineered
biopharmaceuticals.
Schwarz Pharma
Monheim, Germany
SCHWARZ PHARMA is a multinational pharmaceutical company. We strive to serve unmet medical needs by
developing and marketing innovative products for specialty markets. We are committed to providing excellent
services to our customers and creating significant value for our investors.
SICOR, Inc.
Irvine, California
SICOR Inc. is a vertically integrated, multinational pharmac eutical company that focuses on generic finished
dosage injectable pharmaceuticals, active pharmaceutical ingredients, or APIs, and generic
biopharmaceuticals. Using internal research and development capabilities, together with operational flexibility
and manufacturing and regulatory expertise, SICOR is able to take a wide variety of products from the
laboratory to the worldwide market. Leveraging these capabilities, SICOR concentrates on products and
technologies that present significant barriers to entry or offer first-to-market opportunities. SICOR operates
several manufacturing facilities in the U.S., Western and Eastern Europe and Mexico, while maintaining its
corporate headquarters in Irvine, California.
Sepracor, Inc.
Malborough, Massachusetts
Sepracor Inc. is a research-based pharmaceutical company dedicated to treating and preventing human
disease by discovering, developing, and commercializing innovative pharmaceutical products that are directed
toward serving unmet medical needs. Sepracor's drug development program has yielded a portfolio of
pharmaceutical products and candidates with a focus on the treatment of respiratory and central nervous
system disorders. Sepracor's commercialization effor ts are carried out by its U.S.-based, primary care and
specialty-oriented sales force, which is comprised of approximately 1,500 sales professionals, as well as
through out-licensing partnerships.
SkyePharma Inc.
SkyePharma PLC (located in London, UK) develops pharmaceutical products benefiting from world -leading drug
delivery technologies that provide easier-to-use and more effective drug formulations. Currently, there are
nine approved products that incorporate three of SkyePharma's five technologies in the areas of oral,
injectable, inhaled and topical delivery, supported by advanced solubilization capabilities. SkyePharma's US
subsidiary, SkyePharma Inc. (formerly DepoTech Corporation) develops and manufactures injectable,
sustained-release therapeutic products.
Serono, Inc.
Rockland, Massachusetts
As the US affiliate of Serono S.A., a global biotechnology leader headquartered in Geneva, Switzerland,
Serono, Inc. is an integral part of driving the growth and success of the company's global business. For an
overview of Serono, Inc., please read the company's Fact Sheet. To learn more about Serono S.A., please vi sit
the Serono, S.A. website. As a leading U.S. biotechnology company, Serono, Inc. is committed to discovering
and developing medicines that address significant unmet medical needs. Serono has built its reputation as a
leader in the industry by integrating cutting-edge science with comprehensive patient support systems to
improve people's lives. With a focus on specialized therapeutic areas, including reproductive health, neurology
and metabolic endocrinology, we are committed to growing our current therap eutic areas and entering into
new ones by developing both biotherapeutic proteins and small molecules.
Sonus Pharmaceuticals, Inc.
22026 20th Avenue SE
Bothell, Washington 98021
Sonus Pharmaceuticals, Inc. is focused on the development of novel drugs for the treatment of cancer that
offer improved administration, tolerability, safety and effectiveness. The Company continues to advance the
clinical and regulatory development of TOCOSOL Paclitaxel and is in the process of finalizing Phase 3 clinical
testing plans for review by the U.S. Food and Drug Administration. With the promising clinical results to date,
Sonus believes that TOCOSOL Paclitaxel may potentially offer a safer and more effec tive alternative paclitaxel
therapy for cancer patients that is better tolerated and easier -to-use. In addition to executing the plans for
TOCOSOL Paclitaxel, the Company remains focused on driving product and corporate development activities
towards building and expanding its pipeline of oncology product candidates.
Shire plc
Shire is a rapidly growing global specialty pharmaceutical company. We have a global sales and marketing
infrastructure with a broad portfolio of products and our own direct marketing capability in the US, Canada,
UK, Republic of Ireland, France, Germany, Italy and Spain. We also cover the other significant pharmaceutical
markets indirectly through regional distributors. Shire's interest in the Pacific Rim is managed through Shire's
regional office based in Singapore.
Spectrum Pharmaceuticals, Inc.
157 Technology Drive
Irvine, California 92618
Spectrum Pharmaceuticals is an oncology-focused pharmaceutical company engaged in the business of
acquiring, developing and commercializing proprietary drug products which have a primary focus on the
treatment of cancer and related disorders as well as generic drug products for va rious indications. The
Company's lead drug, satraplatin, is a phase 3 oral, anti -cancer drug being co-developed with GPC Biotech AG,
and has been granted fast-track status by the United States Food and Drug Administration (FDA).
Elsamitrucin, a phase 2 drug, will initially target non-Hodgkin's lymphoma. EOquin(TM), a phase 2 drug, is
being studied in the treatment of superficial bladder cancer. SPI-153 (formerly, D-63153), a phase 2 drug, is a
4th generation LHRH antagonist with the potential to treat hormo ne-dependent cancers as well as benign
proliferative disorders, such as benign prostatic hypertrophy and endometriosis. In addition, the Company has
two Abbreviated New Drug Applications for carboplatin and fluconazole, the generic equivalents of Paraplati n®
and Diflucan®, respectively, under active review at the FDA.
Solstice Neurosciences
Solstice Neurosciences, Inc. is a specialty biopharmaceutical company focused on the development,
manufacturing, sales and marketing of specialty biopharmaceutical products. Solstice’s first product,
Myobloc®/NeuroBloc® (Botulinum Toxin Type B) Injectable Solution, represents the only botulinum toxin type
B currently available to physicians and patients worldwide.
STADA Pharmaceuticals USA, INC.
5 Cedar Brook Drive
Cranbury, New Jersey 08512
STADA Pharmaceutical USA, INC. is a wholly owned subsidiary of STADA Arzneimittel AG . Headquartered in
Cranbury, New Jersey is a leading pharmaceutical company specializing in the development and marketing of
generic and branded pharmaceutical products for the U.S. Pharmaceutical market. The generic portfolio covers
all major therapeutic areas with some emphasis on antibiotics. The product development strategy is supported
by active development of new products, licensing and acquisitions. And, the company's foreseeable
opportunities clearly exceed initial expectations by responsiveness to market needs. STADA outsources all of
its manufacturing from world class contract manufacturers in the U.S. and Europe. This allows us to maintain
the highest level of flexibility and market responsiveness, a true benefit for our customers. Distribution of our
products has been outsourced as well, allowing for state of the art innovations in distribution that are aimed at
optimizing service levels. STADA Pharmaceuticals, Inc. distributes its products through wholesalers, chain drug
stores, retail pharmacies, mail order companies, managed Care organizations, hospital groups, nursing home
providers and government agencies.
SuperGen, Inc.
Dublin, California
SuperGen is a pharmaceutical company whose mission is to prolong, improve the quality of and ultimately,
save the lives of those people afflicted with life-threatening diseases, especially cancer. The company
possesses a broad portfolio of proprietary cancer therapies that target a variety of solid tumors, hematological
malignancies and blood disorders, offering renewed hope to patients who suffer from these illnesses. The
company is led by a seasoned management team with extensive experience in all aspects of the oncology
pharmaceutical industry.
Solvay Pharmaceuticals, Inc.
Mariette, Georgia
Solvay Pharmaceuticals is dedicated to optimal patient health management. Our commitment is to contribute
to an increasing portion of corporate growth, revenues and profit. Within our defined therapeutic areas, Solvay
Pharmaceuticals intends to be among the leading global pharmaceuticals companies in providing health
management. We will strengthen our position through global market presence and by marketing a product
portfolio of unique and complete treatments. We will build our product portfolio through discovery,
development, licensing and acquisition of pharmaceuticals. Our success will be based on attracting, developing
and retaining talented and motivated employees with the ability and commitment to excel.
Steiefel Laboratories, Inc.
Stiefel Laboratories is a specialized pharmaceutical company with a singular, steadfast focus o n the
advancement of dermatology and skin care around the world. Stiefel is renowned for its legacy of over 150
years of skin care "firsts", endeavoring to provide the highest quality, most effective prescription and over the
counter skin care products available in over 100 countries. One of our primary missions is to make our
products available in as many countries as possible, as soon as possible. We have a sense of urgency to
improve the quality of life for millions of people around the world.
Synthon Pharmaceuticals, Inc.
Research Triangle Park, North Carolina
Synthon is an independent group of affiliated pharmaceutical companies dedicated to the development,
registration, production, marketing and distribution of a wide range of pharmaceutical products. Founded in
1991, Synthon has developed into a successful and dynamic organization that operates on a global scale.
Synthon's innovative character is reflected by the number of global patents held b y its group members.
Product portfolio selection of sophisticated pharmaceuticals coupled with a fast -track R&D strategy provides a
considerable edge in an increasingly competitive market. Synthon is actively developing several compounds for
commercial introduction.
TabSafe Medical Services
Alpharetta, Georgia
Prescription drug medications are timed released providing a medicine plan scheduled by a pharmacy in a
locked medicine cabinet for senior citizens in assisted living and adult day care community housing centers to
provide accurate and reliable prescription drugs and medication administration by TabSafe Medical Services,
Inc.
Taro Pharmaceuticals U.S.A., Inc.
Hawthorne, New York
Taro markets a broad range of prescription and over-the-counter products in the United States. We are a
leading manufacturer and supplier of topical dermatological products and also have a growing line of sol id
dosage form products used mainly in cardiology and neurology.
Teva Pharmaceuticals North America
North Wales, Pennsylvania
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among t he top 35 pharmaceutical companies
and among the largest generic pharmaceutical companies in the world. Over 80% of Teva's sales are in North
America and Europe. The company develops, manufactures and markets generic and innovative human
pharmaceuticals and active pharmaceutical ingredients.
The Medicines Company
8 Campus Drive
Parsippany, New Jersey 07054
The Medicines Company meets the demands of the world's most advanced medical practiti oners by developing
products that improve specialized care. The Company markets Angiomax® (bivalirudin), an anticoagulant
approved for use in patients undergoing coronary angioplasty procedures. The Medicines Company creates
value using its range of clinical and commercial skills to develop products acquired from leading life science
innovators. The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was
founded in 1996 and employs approximately 150 professionals. In addition to the approved Angiomax product,
The Medicines Company is developing clevidipine, a short-acting calcium channel blocker. The Medicines
Company is also conducting significant clinical research to study potential additional indications for Angiomax
use.
Takeda Pharmaceuticals North America, Inc.
Lincolnshire, Illinois
Takeda Pharmaceuticals North America, Inc. is a new kind of pharmaceutical company. We are dedicated to
serving patients by providing patients with innovative products that mprove their lives with better healthcare.
With a foundation built on the tremendous success of ACTOS (pioglitazone HCl) as well as a robust, early stage
pipeline, TPNA is piosed to realize its vision of becoming a world class Pharmaceutical Company.
Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals, Inc. is a diversified biopharmaceutical company focused on the development and
commercialization of novel treatments for central nervous system (CNS) disorders, cancer and other serious
and life-threatening diseases. The company’s numerous products in development utilize innovative
technologies that have the potential to significantly improve the treatment of these diseases. Titan also
establishes important partnerships with multinational pharmaceutical companies and government institutions
for the development of its products.
TAP Pharmaceutical Products, Inc.
Lake Forest, Illinois
At TAP, we are connected to patients, to customers, and to each other. TAP is committed to working and living
by the values in which we believe, and we are guided in our decisions by the mission we own together. We call
these core values the Spirit of TAP.
Transkaryotic Therapies Inc. (TKT)
TKT is a leading biotechnology company developing and commercializing human prot eins for a broad range of
diseases, with a major focus on rare genetic diseases. TKT currently markets one product, Replagal(TM)
(agalsidase alfa) for the treatment of Fabry Disease in the European Union and certain other countries and has
four products in clinical testing. TKT is headquartered in Cambridge, Massachusetts and has a majority owned
subsidiary in Sweden, TKT Europe-5S AB, which is responsible for European sales and marketing activities.
TEAMM Pharmaceuticals
Tampa, Florida
Accentia BioPharmaceuticals, Inc (Nasdaq:ABPI) is a vertically-integrated specialty biopharmaceutical
company, formed by the Hopkins Capital Group, LLC and affiliates to acquire late -stage targeted therapeutics
and to use patented delivery technologies to enhance the performance of these therapeutics. The Company
consists of two wholly-owned subsidiaries, and a majority, controlling interest in a third company. Together,
these assets provide for a comprehensive abili ty to commercialize biopharmaceuticals.
Triangle Pharmaceuticals, Inc.
Durham, North Carolina
Triangle Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the development of new
antiviral drug candidates, with a particular focus on t herapies for the human immunodeficiency virus (HIV) and
the hepatitis B virus. Triangle's proprietary drug candidates under development for HIV and/or hepatitis B
include Coviracil(R) (emtricitabine), amdoxovir (formerly DAPD) and clevudine (formerly L -FMAU)
UCB Pharma
Brussels, Belgium
UCB is a leading global biopharmaceutical company dedicated to the research, development and
commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous
system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB
focuses on securing a leading position in severe disease categories.
Upsher-Smith Laboratories, Inc.
Maple Grove, Minnesota
Since 1919, Upsher-Smith Laboratories, Inc. has grown into one of the world’s top pharmaceutical companies.
This growth is due to our company’s quest for Excellence through Innovation. With state-of-the-art facilities
located in Minneapolis, Minnesota and Denver, Colorado, we develop, manufacture, and market an array of
products that advance human health. Our proven legacy of excellence and ongoing focus on innovation
establish a foundation for our continued success.
Valeant Pharmaceuticals International
Costa Mesa, California
Valeant Pharmaceuticals International (NYSE: VRX, effective November 14, 2003) is a global, publicly traded,
research-based specialty pharmaceutical company that discovers, develops, manufactures and markets a
broad range of pharmaceutical products. (NOTE: Formerly known as ICN Pharmaceuticals)
Vela Pharmaceuticals
Lawrenceville, New Jersey
Demand for medicines to treat psychiatric and neurological disorders is huge and growing. Worldwide spending
for these therapies exceeded $46 billion in 2001. The Central Nervous S ystem (CNS) medication market is the
fastest growing of any major therapeutic area. Vela Pharmaceuticals Inc. (VelaPharm) "rediscovers" and
develops CNS medicines. By starting with molecules that have already been tested in humans, VelaPharm
minimizes the risks of traditional drug discovery and development. Partnering with VelaPharm is an attractive
alternative for pharmaceutical companies with assets on the backburner. Taking full or partial ownership of
such assets, the VelaPharm team puts it all into safe, efficient and fast development. The Company's ability to
design and run optimal Phase II CNS programs is second to none. VelaPharm already has several promising
assets in clinical development. VelaPharm is led by experienced CNS pharmaceutical and CRO e xecutives.
VelaPharm's President and CEO is Kevin L. Keim, Ph.D., the former president of Quintiles' CNS Therapeutics
group. He has recruited top performers from such organizations as Quintiles, Wyeth -Ayerst, Roche, Merck &
Co., McKinsey & Company, and the National Institute of Mental Health. Based in Lawrenceville, NJ, VelaPharm
was incorporated in 1998. The company is backed by venture funding from JP Morgan Partners, New Enterprise
Associates, Venrock, and others.
Valera Pharmaceuticals
Cranbury, New Jersey
Valera Pharmaceuticals was founded in 1972 and has since established a wealth of expertise in the technology
of specialty blends of hydrogel polymers, the science that led to the development of soft contact lenses.
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a global biotechnology company. Vertex seeks to
discover, develop, and commercialize major pharmaceutical products independently and with partners.
Chemogenomics, Vertex's proprietary, systematic, genomics -based platform, is designed to accelerate the
discovery of new drugs and to expand intellectual property coverage of drug candidate compounds and classes
of related compounds. This approach, which targets gene families, has formed the basis for several
commercial collaborations under which Vertex retains rights to downstream revenue. Vertex's first approved
product is Agenerase® (amprenavir), an HIV protease inhibitor, which Vertex co-promotes with
GlaxoSmithKline. Vertex has more than 12 drug candidates in clinical and preclinical development to treat viral
diseases, inflammation, cancer, autoimmune diseases, neurologic al disorders and genetic disorders.
Ventiv Health
Somerset, New Jersey
inVentiv is uniquely equipped to meet the needs of large pharmaceutical companies, as well as small to mid sized companies, with solutions that are tailored to meet each client's specific needs. Through its three
divisions - inVentiv Clinical, inVentiv Communications and inVentiv Commercial - inVentiv Health can support a
pharmaceutical product at any point in the product life cycle. By outsourcing key functions to inVentiv,
pharmaceutical companies stay focused on their core competencies, enabling quality products to be marketed
more rapidly, more flexibly, and with lower costs.
Vysis, Inc.
Downers Grove, Illinois
Vysis, Inc., a wholly-owned subsidiary of Abbott Laboratories, is a leading Genomic Disease Management
company that develops, commercializes and markets DNA-based clinical products providing information critical
to the evaluation and management of cancer, prenatal disorders and other genetic diseases. Vysis, originally
Imagenetics Incorporated, was incorporated in 1991 as a division of Amoco Technology Company (a wholly owned subsidiary of Amoco Corporation), and made its initial public offering of stock in 1998. The company
was listed on the NASDAQ® stock exchange between 1998 and 2001. In October, 2001, Abbott Laboratories
acquired Vysis as a wholly-owned subsidiary. The transaction was completed on December 5, 2001.
Vernalis plc
Morristown, New Jersey
Vernalis is a UK-based specialty bio-pharmaceutical company with two marketed products, Apokyn® to treat
immobilising "off" episodes in patients with advanced Parkinson's disease and Frova®, to treat migraine. The
company has a broad development pipeline focused on neurology and central nervous system disorders.
Verus Pharmaceuticals, Inc
We are a pediatric-oriented company dedicated to identifying, developing and delivering solutions to address
the unmet medical needs of children and those who care for them. We are building our initial franchise
position in the treatment of asthma, allergies, and related diseases and conditions.
Watson Pharmaceuticals, Inc.
Corona, California
Watson Pharmaceuticals, Inc. has evolved into a specialty pharmaceutical company, focused on d eveloping,
manufacturing and marketing brand and generic pharmaceutical products utilizing various drug delivery
technologies. These technologies include solid dosage form, oral controlled release, transdermal, oral
transmucosal and drug cell targeting delivery systems.
Wyeth
Madison, New Jersey
Wyeth (formerly American Home Products Corporation) is a research -based, global pharmaceutical company
responsible for the discovery and development of some of today's most innovative medicines. Our products are
sold in more than 140 countries, and our product portfolio includes innovative treatments across a wide range
of therapeutic areas. Our worldwide resources include more than 52,000 employees, manufacturin g facilities
on five continents, and a discovery and development platform encompassing pharmaceuticals, vaccines and
biotechnology.
Warner Chilcott PLC
Larne, North Ireland
Warner Chilcott PLC is a specialty pharmaceutical company focused on two core therapeutic areas: women’s
healthcare and dermatology. The acquisition of our U.S. subsidiary in October 2000 afforded us access to the
U.S. pharmaceuticals market where we have achieved impressive growth. Since then, we have invested further
in building our U.S. pharmaceuticals business. We completed the disposal of the pharmaceutical services
businesses in 2003 and in 2004, disposed of the U.K.-based pharmaceutical product sales and marketing
business, a the U.K.-based sterile solutions business, thereby continuing to improve margins and release
resources that have been and will be reinvested in the U.S. pharmaceutical business.
Xenon Pharmaceuticals Inc.
3650 Gilmore Way
Burnaby, BC, Canada V5G 4W8
Xenon Pharmaceuticals Inc. is a privately owned, clinical genetics -based drug discovery and development
company engaged in developing small molecule therapies based on the genetic causes of select metabolic,
neurological and cardiovascular diseases.
XOMA (US) LLC
2910 Seventh Street
Berkeley, California 94710
XOMA develops and manufactures antibody and other protein-based biopharmaceuticals for disease targets
that include immunological and inflammatory disorders, cancer and infectious diseases. XOMA's programs
include collaborations: with Genentech, Inc. on the Raptiva(TM) antibody for psoriasis (BLA submission),
psoriatic arthritis (Phase II) and other indications; and with Millennium Pharmaceuticals, Inc. on two
biotherapeutic agents, CAB-2 and MLN2201, for vascular inflammation indications (preclinical and phase I,
respectively). Earlier-stage development programs focus on antibodies and other compounds developed by
XOMA for the treatment of cancer, retinopathies and acne.

Pharmaceutical Company List

Transcription

Similar documents